



02.07.2025

**11:30 - 12:30**      **Type: Industry Satellite Symposium**      **Room Madrid**  
**Title: Revolution Medicines - Evolving treatment strategies in metastatic pancreatic adenocarcinoma: Current and emerging therapeutic approaches and the role of RAS**

11:30 - 11:45      **Current standard of care therapies for metastatic pancreatic adenocarcinoma**

11:45 - 12:00      **Targeted therapeutic approaches in rare pancreatic cancer subsets**

12:00 - 12:15      **RAS mutations: A key oncogenic driver in pancreatic cancer**

12:15 - 12:30      **Advances in RAS-targeted therapies: Mutant-selective to multi-selective RAS inhibitors**

**11:30 - 12:30**      **Type: Industry Satellite Symposium**      **Room Bilbao**  
**Title: BMS - Advancing GI oncology: Changing landscape in CRC, HCC, and pancreatic cancer**  
Chair(s): Sara De Dosso, Switzerland

11:30 - 11:31      **Welcome and introduction**  
Sara De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

11:31 - 12:01      **HCC at a crossroads: Is it prime time for new options?**  
Maria Elisa Reig Monzon<sup>1</sup>, Peter Galle<sup>2</sup>, <sup>1</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, Spain, <sup>2</sup>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany

12:01 - 12:20      **Clinical advances in MSI-H/dMMR mCRC**  
Sara De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

12:20 - 12:29      **Emerging therapies in GI cancers**  
Sara De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

12:29 - 12:30      **Summary and close**  
Sara De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland



**11:30 - 12:30** **Type: Industry Satellite Symposium** **Room Malaga**  
**Title: PeerVoice - Shifting the paradigm in biliary tract cancers: Contemporary data and decision-making**  
 Chair(s): Lorenza Rimassa, Italy

11:30 - 11:32 **Welcome and introduction**  
Lorenza Rimassa, IRCCS Humanitas Research Hospital, Rozzano, Italy

11:32 - 11:47 **Appreciating the expanding evidence guiding personalised medicine in biliary tract cancers**  
John Bridgewater, UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom

11:47 - 12:17 **Managing biliary tract cancers in the modern era: Clinical experiences in individualised treatment**  
Lorenza Rimassa<sup>1</sup>, John Bridgewater<sup>2</sup>, Julien Edeline<sup>3</sup>, <sup>1</sup>IRCCS Humanitas Research Hospital, Rozzano, Italy, <sup>2</sup>UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom, <sup>3</sup>Centre Eugene - Marquis, Rennes, France

12:17 - 12:27 **Continuing the conversation in biliary tract cancers: Expert insights on your compelling questions**  
Lorenza Rimassa<sup>1</sup>, John Bridgewater<sup>2</sup>, Julien Edeline<sup>3</sup>, <sup>1</sup>IRCCS Humanitas Research Hospital, Rozzano, Italy, <sup>2</sup>UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom, <sup>3</sup>Centre Eugene - Marquis, Rennes, France

12:27 - 12:30 **Final remarks, conclusions, and closing**  
Lorenza Rimassa, IRCCS Humanitas Research Hospital, Rozzano, Italy

**11:30 - 12:30** **Type: ESMO Colloquium** **Room Valencia**  
**Title: ESMO Colloquium supported by Novocure - Non-surgical, non-pharmaceutical treatment modalities: Research breakthroughs for the control of gastrointestinal cancers**  
 Chair(s): Teresa Macarulla Mercade, Spain; Maaïke Berbee, Netherlands

11:30 - 11:33 **Welcome and introduction**  
Teresa Macarulla Mercade, VHIO - Vall d'Hebron Institute of Oncology, Barcelona, Spain

11:33 - 11:48 **Innovative local ablative techniques for the control of metastases from gastrointestinal cancers**  
Thomas Helmberger, München Klinikum Bogenhausen, Munich, Germany

11:48 - 12:03 **Mechanisms of action of electrical current-based tumour treating fields and ongoing clinical research in gastrointestinal malignancies**  
Teresa Macarulla Mercade, VHIO - Vall d'Hebron Institute of Oncology, Barcelona, Spain

12:03 - 12:18 **Novel radiation therapy approaches for oligometastases from gastrointestinal tumours**  
Maaïke Berbee, Maastricht University Medical Center (MUMC), Maastricht, Netherlands



|               |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                       |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| 12:18 - 12:28 | <b>Q&amp;A and discussion</b>                                                                                                                                                                                                                                                                                                                                                                                                         |                       |
| 12:28 - 12:30 | <b>Concluding remarks</b><br><u>Maaïke Berbee</u> , Maastricht University Medical Center (MUMC), Maastricht, Netherlands                                                                                                                                                                                                                                                                                                              |                       |
| 12:30 - 13:00 | <b>Type: Coffee break</b><br><b>Title: Welcome reception</b>                                                                                                                                                                                                                                                                                                                                                                          | <b>Foyer</b>          |
| 13:00 - 14:00 | <b>Type: Keynote session</b><br><b>Title: Welcome to the ESMO Gastrointestinal Cancers Congress 2025 and Keynote addresses</b><br>Chair(s): Michel Ducreux, France; Teresa Macarulla Mercade, Spain; Eric Van Cutsem, Belgium                                                                                                                                                                                                         | <b>Room Barcelona</b> |
| 13:00 - 13:05 | <b>Welcome to the ESMO Gastrointestinal Cancers Congress 2025</b><br><u>Michel Ducreux</u> <sup>1</sup> , <u>Teresa Macarulla Mercade</u> <sup>2</sup> , <u>Eric Van Cutsem</u> <sup>3</sup> , <sup>1</sup> Gustave Roussy - Cancer Campus, Villejuif, France, <sup>2</sup> VHIO - Vall d'Hebron Institute of Oncology, Barcelona, Spain, <sup>3</sup> UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium |                       |
| 13:05 - 13:08 | <b>Introduction to the Keynote Speaker 1</b>                                                                                                                                                                                                                                                                                                                                                                                          |                       |
| 13:08 - 13:33 | <b>Molecular biology insights in pancreatic cancer</b><br><u>Anirban Maitra</u> , The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America                                                                                                                                                                                                                                                |                       |
| 13:33 - 13:36 | <b>Introduction to Keynote Speaker 2</b>                                                                                                                                                                                                                                                                                                                                                                                              |                       |
| 13:36 - 14:01 | <b>Epidemiology: Trends and causes of gastrointestinal cancers</b><br><u>Elisabete Weiderpass</u> , IARC - International Agency for Research on Cancer, Lyon, France                                                                                                                                                                                                                                                                  |                       |
| 14:15 - 15:45 | <b>Type: Educational session</b><br><b>Title: Pancreatic cancer</b><br>Chair(s): Eileen O'Reilly, United States of America                                                                                                                                                                                                                                                                                                            | <b>Room Barcelona</b> |
| 14:15 - 14:35 | <b>Surgery of pancreatic cancer: How far is too far?</b><br><u>Massimo Falconi</u> , IRCCS Ospedale San Raffaele, Milan, Italy                                                                                                                                                                                                                                                                                                        |                       |
| 14:35 - 14:55 | <b>Treatment of locally advanced disease</b><br><u>Karyn Goodman</u> , Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States of America                                                                                                                                                                                                                                                            |                       |
| 14:55 - 15:15 | <b>Oligometastatic pancreatic cancer treatment</b><br><u>Oliver Strobel</u> , MedUni Wien - Universitätsklinik für Psychiatrie und Psychotherapie, Wien, Austria                                                                                                                                                                                                                                                                      |                       |



15:15 - 15:35 **Metastatic disease: Treatment strategy in 2025**

Cindy Neuzillet, Institut Curie, Paris, France

15:35 - 15:45 **Q&A**

|                      |                                                                                                             |                    |
|----------------------|-------------------------------------------------------------------------------------------------------------|--------------------|
| <b>14:15 - 15:30</b> | <b>Type: Multidisciplinary Tumour Board</b><br><b>Title: GI NET</b><br>Chair(s): Rachel Riechelmann, Brazil | <b>Room Madrid</b> |
|----------------------|-------------------------------------------------------------------------------------------------------------|--------------------|

14:15 - 14:25 **Neuroendocrine carcinoma**

Rocio Garcia-Carbonero, University Hospital 12 De Octubre, Madrid, Spain

14:25 - 14:40 **Voting and Q&A**

Rocio Garcia-Carbonero, University Hospital 12 De Octubre, Madrid, Spain

14:40 - 14:50 **Functional NET with refractory carcinoid syndrome**

Rachel Riechelmann, A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, Brazil

14:50 - 15:05 **Voting and Q&A**

Rachel Riechelmann, A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, Brazil

15:05 - 15:15 **Advanced well-differentiated G 2 and 3 pancreatic NET**

Sara De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

15:15 - 15:30 **Voting and Q&A**

Sara De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

|                      |                                                         |              |
|----------------------|---------------------------------------------------------|--------------|
| <b>15:45 - 16:15</b> | <b>Type: Coffee break</b><br><b>Title: Coffee break</b> | <b>Foyer</b> |
|----------------------|---------------------------------------------------------|--------------|

|                      |                                                                                             |                       |
|----------------------|---------------------------------------------------------------------------------------------|-----------------------|
| <b>16:15 - 17:35</b> | <b>Type: Abstract session</b><br><b>Title: Mini Oral session - Innovation in GI cancers</b> | <b>Room Barcelona</b> |
|----------------------|---------------------------------------------------------------------------------------------|-----------------------|

16:15 - 16:20 **One LBA to announced**

16:20 - 16:25 **One LBA to announced**

16:25 - 16:30 **260MO - AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)—Cohort B progression free survival (PFS) results.**

Andrew Dean, Saint John of God Subiaco Hospital, Subiaco, Australia



|                      |                                                                                                                                                                                                                                                                                                                                                                                                    |                    |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| 16:30 - 16:45        | <b>Invited discussant 2 LBAs to be announced and 260MO</b>                                                                                                                                                                                                                                                                                                                                         |                    |
| 16:45 - 16:50        | <b>One LBA to announced</b>                                                                                                                                                                                                                                                                                                                                                                        |                    |
| 16:50 - 16:55        | <b>388MO - Preliminary Safety and Efficacy of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody, in Combination with Nivolumab and mFOLFOX in Metastatic Gastroesophageal Carcinoma (mGEC)</b><br><u>Samuel Klempner</u> , Massachusetts General Hospital, Boston, United States of America                                                                                               |                    |
| 16:55 - 17:00        | <b>6MO - Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1</b><br><u>Dirk Arnold</u> , AK Altona, Hamburg, Germany                                                                                                                    |                    |
| 17:00 - 17:15        | <b>Invited discussant 1 LBA to be announced, 388MO and 6MO</b>                                                                                                                                                                                                                                                                                                                                     |                    |
| 17:15 - 17:20        | <b>149MO - Irpagratinib (ABSK-011) plus Atezolizumab in Frist-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study</b><br><u>Qi Cheng</u> , Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Chibi City, China |                    |
| 17:20 - 17:25        | <b>150MO - Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis</b><br><u>Stephen Chan</u> , The Chinese University of Hong Kong, Hong Kong SAR, China                                                                                               |                    |
| 17:25 - 17:35        | <b>Invited discussant 149MO and 150MO</b>                                                                                                                                                                                                                                                                                                                                                          |                    |
| <b>16:15 - 17:45</b> | <b>Type: Educational session</b><br><b>Title: Localised colon cancer</b><br>Chair(s): Jenny Seligmann, United Kingdom                                                                                                                                                                                                                                                                              | <b>Room Madrid</b> |
| 16:15 - 16:35        | <b>Endoscopic resection of early colon cancer</b><br><u>Thomas Rösch</u> , University Medical Center Hamburg-Eppendorf, Hamburg, Germany                                                                                                                                                                                                                                                           |                    |
| 16:35 - 16:55        | <b>Use of ctDNA in treatment strategy</b><br><u>Clara Montagut Viladot</u> , Hospital del Mar - Parc de Salut Mar, Barcelona, Spain                                                                                                                                                                                                                                                                |                    |
| 16:55 - 17:15        | <b>New molecular markers, Immunoscore and others</b><br><u>Pierre Laurent-Puig</u> , Université Paris Cité, Paris, France                                                                                                                                                                                                                                                                          |                    |



17:15 - 17:35 **How to select patients for neoadjuvant treatment**  
Jenny Seligmann, The University of Leeds, Leeds, United Kingdom

17:35 - 17:45 **Q&A**

**16:15 - 17:45** **Type: Special session** **Room Valencia**  
**Title: ESDO special session - ESDO session - More with less: The potential of de-escalated therapy in advanced GI cancers**  
Chair(s): Michela Guardascione, Italy; Piotr Wysocki, Poland

16:15 - 16:35 **Tailored dosing in advanced upper GI and pancreatobiliary cancers: A feasible path to optimize care**  
Piotr Wysocki, University Clinical Center MUG, Gdansk, Poland

16:35 - 16:55 **Reducing chemotherapy dosing in advanced colorectal cancer: Balancing safety and efficacy**  
Lucjan Wyrwicz, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

16:55 - 17:15 **The role of bolus 5-FU in multidrug regimens for GI malignancies: Essential or obsolete?**  
Zineb Benbrahim, CHU - Centre Hospitalier Universitaire Hassan II, Fez, Morocco

17:15 - 17:35 **Safety first: Evaluating the evidence for maintenance first-line therapy in advanced GI cancers**  
Michela Guardascione, CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, Italy

17:35 - 17:45 **Q&A**

**18:00 - 19:00** **Type: Industry Satellite Symposium** **Room Bilbao**  
**Title: Astellas - Characterising advanced G/GEJ adenocarcinoma: How can we personalise targeted treatment?**  
Chair(s): Maria Alsina Maqueda, Spain

18:00 - 18:05 **Today's clinic: Case-based exploration of advanced G/GEJ adenocarcinoma**  
Maria Alsina Maqueda, Hospital Universitario de Navarra, Pamplona, Spain

18:05 - 18:15 **Profiling Hermione, Claude and Imogen: Identifying patient populations**  
Jean Christophe Sabourin, Hopital Charles-Nicolle - CHU de Rouen, Rouen, France



18:15 - 18:45 **Spotlighting personalised treatment: A case-based approach**  
Maria Alsina Maqueda<sup>1</sup>, Sylvie Lorenzen<sup>2</sup>, <sup>1</sup>Hospital Universitario de Navarra, Pamplona, Spain,  
<sup>2</sup>Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, Germany

18:45 - 19:00 **Personalised treatment: How far have we come?**  
Maria Alsina Maqueda<sup>1</sup>, Sylvie Lorenzen<sup>2</sup>, Jean Christophe Sabourin<sup>3</sup>, <sup>1</sup>Hospital Universitario de Navarra, Pamplona, Spain, <sup>2</sup>Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, Germany, <sup>3</sup>Hopital Charles-Nicolas - CHU de Rouen, Rouen, France

**18:00 - 19:00** **Type: Industry Satellite Symposium** **Room Malaga**  
**Title: AbbVie - Solving the mystery of targeting c-met in colorectal cancer (CRC) and beyond**  
Chair(s): Chiara Cremolini, Italy

18:00 - 18:10 **c-Met: Highlighting un-MET need in oncology**  
Chiara Cremolini, University of Pisa, Pisa, Italy

18:10 - 18:25 **Assessing the trials, tribulations, and lessons of c-met targeting**  
Gunnar Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany

18:25 - 18:40 **Reinventing the way c-met is targeted in metastatic CRC**  
Chiara Cremolini, University of Pisa, Pisa, Italy

18:40 - 18:55 **Panel discussion and Q&A**  
Chiara Cremolini<sup>1</sup>, Gunnar Folprecht<sup>2</sup>, <sup>1</sup>University of Pisa, Pisa, Italy, <sup>2</sup>Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany

18:55 - 19:00 **Closing**

**18:00 - 19:00** **Type: Industry Satellite Symposium** **Room Valencia**  
**Title: Pfizer -Cancer cachexia in gastrointestinal malignancies**  
Chair(s): Marie Fallon, United Kingdom

18:00 - 18:15 **Cancer cachexia overview: Epidemiology, impacts on patients, pathophysiology and underlying mechanisms**  
Marie Fallon, Cancer Research UK Edinburgh Centre, Edinburgh, United Kingdom

18:15 - 18:30 **Diagnosing cachexia: Challenges in identifying the disease, criteria and assessment tools**  
Reinhold Gellner, University Münster, Münster, Germany



- 18:30 - 18:45      **Current treatment options: Nutrition, pharmacological, multidisciplinary approaches and supportive care**  
Pascal Hammel, APHP, hopital Paul Brousse, VILLEJUIF, France
- 18:45 - 19:00      **Future landscape: Emerging therapies, novel drug targets, GDF-15 & ponesimomab**  
Naureen Starling, The Royal Marsden Hospital - Chelsea, London, United Kingdom





03.07.2025

**08:30 - 09:45**      **Type: Multidisciplinary Tumour Board**      **Room Madrid**  
**Title: Rectal cancer**  
Chair(s): Gerald Prager, Austria

08:30 - 08:40      **Oligometastatic rectal cancer**  
Gerald Prager, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, Austria

08:40 - 08:55      **Voting and Q&A**  
Gerald Prager, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, Austria

08:55 - 09:05      **Intermediate risk middle rectal cancer**  
Julio Garcia-Aguilar, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America

09:05 - 09:20      **Voting and Q&A**  
Julio Garcia-Aguilar, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America

09:20 - 09:30      **Organ preservation in lower rectal cancer**  
Veronique Vendrely, CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, France

09:30 - 09:45      **Voting and Q&A**  
Veronique Vendrely, CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, France

**08:45 - 09:45**      **Type: Controversy session**      **Room Barcelona**  
**Title: Germline testing for all pancreatic cancer patients**  
Chair(s): Erika Ruiz, Mexico

08:45 - 08:55      **Introduction**  
Erika Ruiz, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico

08:55 - 09:15      **Pro**  
Talia Golan, Sheba Tel Hashomer Medical Center, Ramat Gan, Israel

09:15 - 09:35      **Con**  
Eileen O'Reilly, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, United States of America

09:35 - 09:45      **Q&A and discussion**  
Erika Ruiz, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico



|                      |                                                                                                                 |                       |
|----------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------|
| <b>10:00 - 10:30</b> | <b>Type: Keynote session</b><br><b>Title: Decoding genome and transcriptome signatures in colorectal cancer</b> | <b>Room Barcelona</b> |
|----------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------|

10:00 - 10:05 **Introduction to the Keynote Speaker**

10:05 - 10:30 **Decoding genome and transcriptome signatures in colorectal cancer**  
Federica Di Nicolantonio, IRCCS - Istituto di Candiolo - FPO, Candiolo, Italy

|                      |                                                         |              |
|----------------------|---------------------------------------------------------|--------------|
| <b>10:30 - 11:00</b> | <b>Type: Coffee break</b><br><b>Title: Coffee break</b> | <b>Foyer</b> |
|----------------------|---------------------------------------------------------|--------------|

|                      |                                                                                                                      |                       |
|----------------------|----------------------------------------------------------------------------------------------------------------------|-----------------------|
| <b>11:00 - 12:30</b> | <b>Type: Special Symposium</b><br><b>Title: Innovation in GI oncology</b><br>Chair(s): Jakob Nikolas Kather, Germany | <b>Room Barcelona</b> |
|----------------------|----------------------------------------------------------------------------------------------------------------------|-----------------------|

11:00 - 11:20 **Innovation and AI in GI pathology**  
Magali Svrcek, Sorbonne Université, Paris, France

11:20 - 11:40 **AI in GI oncology**  
Jakob Nikolas Kather, Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine, Dresden, Germany

11:40 - 12:00 **Radioligand-based therapies**  
Christophe Deroose, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium

12:00 - 12:20 **Proton therapy: Present and future in GI oncology**  
Karin Haustermans, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium

12:20 - 12:30 **Q&A**

|                      |                                                                                                                        |                    |
|----------------------|------------------------------------------------------------------------------------------------------------------------|--------------------|
| <b>11:00 - 12:30</b> | <b>Type: Educational session</b><br><b>Title: Hepatocellular carcinoma</b><br>Chair(s): Maria Elisa Reig Monzon, Spain | <b>Room Madrid</b> |
|----------------------|------------------------------------------------------------------------------------------------------------------------|--------------------|

11:00 - 11:20 **Global strategy of treatment of hepatocellular carcinoma**  
Maria Elisa Reig Monzon, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

11:20 - 11:40 **Surgery and liver transplantation in 2025**  
Vincenzo Mazzaferro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

11:40 - 12:00 **Intermediate stage: A new reality for medical oncologists?**  
Tanios Bekaii-Saab, Mayo Clinic Cancer Center, Phoenix, United States of America



12:00 - 12:20 **New medical treatment in 2025 beyond IO combinations**  
Stephen Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, Hong Kong SAR, China

12:20 - 12:30 **Q&A**

**12:45 - 13:45** **Type: Industry Satellite Symposium** **Room Madrid**  
**Title: MSD - Optimizing immune-oncology strategies in first-line gastric cancer: From biomarkers to therapeutic impact**  
Chair(s): Fernando Rivera Herrero, Spain

12:45 - 12:50 **Opening remarks**  
Fernando Rivera Herrero, HUMV - Hospital Universitario Marques de Valdecilla, Santander, Spain

12:50 - 13:02 **Maximizing outcomes: The role of PD-L1, HER2, and MSI testing in guiding treatment decisions**  
Fernando Rivera Herrero, HUMV - Hospital Universitario Marques de Valdecilla, Santander, Spain

13:02 - 13:15 **Precision matters: Ensuring optimized tumor Sampling and testing for reliable results**  
Nicole Van Grieken, Vrije University Medical Centre (VUMC), Amsterdam, Netherlands

13:15 - 13:27 **Navigating the first-line landscape of HER2 positive GC/GEJ cancer treatments**  
Peter Thuss-Patience, Vivantes Klinikum im Friedrichshain, Berlin, Germany

13:27 - 13:40 **Fine tuning the first-line treatment of HER2 negative GC/GEJ In low PD-L1 expressors**  
Sara Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padua, Italy

13:40 - 13:45 **Closing remarks**  
Fernando Rivera Herrero, HUMV - Hospital Universitario Marques de Valdecilla, Santander, Spain

**12:45 - 13:45** **Type: Industry Satellite Symposium** **Room Bilbao**  
**Title: AstraZeneca - Examining current approaches and future prospects for the management of hepatobiliary cancers**  
Chair(s): Stephen Chan, Hong Kong SAR, China

12:45 - 12:50 **Welcome and introductions**  
Stephen Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, Hong Kong SAR, China

12:50 - 13:00 **Current immunotherapy-based approaches in the management of advanced unresectable HCC**  
Stephen Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, Hong Kong SAR, China



- 13:00 - 13:15 **Case study discussion with audience Q&A: Considerations for the evolving clinical management of advanced unresectable HCC**  
Andrea Casadei Gardini, UniSR - Università Vita e Salute San Raffaele Milano, Milan, Italy
- 13:15 - 13:25 **Evolving treatment landscape and future outlook for patients across the BTC continuum**  
Arndt Vogel, University of Toronto - Institute of Medical Science, Toronto, Canada
- 13:25 - 13:40 **Case study discussion with audience Q&A: Clinical considerations for the diagnosis and management of BTC**  
Beatriz García-Paredes, Hospital Clinico Universitario San Carlos, Madrid, Spain
- 13:40 - 13:45 **Audience Q&A**  
Stephen Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, Hong Kong SAR, China

**12:45 - 13:45** **Type: Industry Satellite Symposium** **Room Malaga**  
**Title: Merck - Expanding treatment horizons: Advancements in key mCRC populations**  
Chair(s): Clara Montagut Viladot, Spain

- 12:45 - 12:50 **Welcome and introduction**  
Clara Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
- 12:50 - 13:05 **Optimizing 1L therapy in RAS wt mCRC: A wealth of evidence**  
Sebastian Stintzing, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 13:05 - 13:25 **Moving forward: The evolving treatment landscape for BRAF V600E mt mCRC**  
Clara Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
- 13:25 - 13:40 **Looking to the horizon: Exploring novel treatment strategies in mCRC**  
Erika Martinelli, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
- 13:40 - 13:45 **Q&A/Panel discussion**  
Clara Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain

**12:45 - 13:45** **Type: Industry Satellite Symposium** **Room Valencia**  
**Title: Servier - Navigating through the evolving treatment pathways in mCRC: Insights and practical implications**  
Chair(s): Julien Taieb, France; Elena Elez Fernandez, Spain

- 12:45 - 12:50 **Introduction**  
Julien Taieb, Hopital European George Pompidou, Paris, France
- 12:50 - 13:00 **Exploring therapeutic strategies in mCRC: A case-based discussion**  
Claire Gallois, HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, France



|                      |                                                                                                                                                                                                                   |                       |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| 13:00 - 13:10        | <b>Current landscape of 1L and 2L mCRC</b><br><u>Julien Taieb</u> , Hopital European George Pompidou, Paris, France                                                                                               |                       |
| 13:10 - 13:30        | <b>Latest insights in 3L mCRC: Towards optimal sequencing for the patient</b><br><u>Dominik Modest</u> , Charité - Universitaetsmedizin Berlin, Berlin, Germany                                                   |                       |
| 13:30 - 13:40        | <b>Treatment approaches in later lines for mCRC</b><br><u>Elena Elez Fernandez</u> , Vall d'Hebron University Hospital, Barcelona, Spain                                                                          |                       |
| 13:40 - 13:45        | <b>Conclusion</b><br><u>Elena Elez Fernandez</u> , Vall d'Hebron University Hospital, Barcelona, Spain                                                                                                            |                       |
| <b>12:45 - 13:30</b> | <b>Type: Young Oncologists session</b><br><b>Title: YO Mentorship session: Building lasting international collaborations</b><br>Chair(s): Deniz Can Guven, Türkiye; Rille Pihlak, United Kingdom                  | <b>Foyer</b>          |
| 12:45 - 13:30        | <b>Table 3: Building lasting international collaborations</b><br><u>Sara De Dosso</u> , EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland |                       |
| <b>12:45 - 13:30</b> | <b>Type: Young Oncologists session</b><br><b>Title: YO Mentorship session: Using AI for scientific research</b><br>Chair(s): Deniz Can Guven, Türkiye; Rille Pihlak, United Kingdom                               | <b>Foyer</b>          |
| 12:45 - 13:30        | <b>Table 2: Using AI for scientific research</b><br><u>Jakob Nikolas Kather</u> , Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine, Dresden, Germany                                        |                       |
| <b>12:45 - 13:30</b> | <b>Type: Young Oncologists session</b><br><b>Title: YO Mentorship session: Integrating research into everyday clinical practice</b><br>Chair(s): Deniz Can Guven, Türkiye; Rille Pihlak, United Kingdom           | <b>Foyer</b>          |
| 12:45 - 13:30        | <b>Table 1: Integrating Research into everyday clinical practice</b><br><u>Demetris Papamichael</u> , Bank of Cyprus Oncology Centre, Nicosia, Cyprus                                                             |                       |
| <b>14:00 - 15:30</b> | <b>Type: Abstract session</b><br><b>Title: Proffered Paper session</b>                                                                                                                                            | <b>Room Barcelona</b> |
| 14:00 - 14:10        | <b>One LBA to announced</b>                                                                                                                                                                                       |                       |
| 14:10 - 14:20        | <b>One LBA to announced</b>                                                                                                                                                                                       |                       |



|                      |                                                                                                                                                                                                                                                                                                                                                                                 |              |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| 14:20 - 14:30        | <b>10 - Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): health-related quality of life (HRQoL) analyses from CheckMate 8HW</b><br><u>Elena Elez Fernandez</u> , Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain |              |
| 14:30 - 14:40        | <b>Invited Discussant 2 LBAs to be announced and 10</b>                                                                                                                                                                                                                                                                                                                         |              |
| 14:40 - 14:50        | <b>Q&amp;A</b>                                                                                                                                                                                                                                                                                                                                                                  |              |
| 14:50 - 15:00        | <b>One LBA to announced</b>                                                                                                                                                                                                                                                                                                                                                     |              |
| 15:00 - 15:10        | <b>1480 - Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d/c) due to treatment-related adverse events (TRAEs): results from CheckMate 9DW</b><br><u>Bruno Sangro</u> , Clínica Universidad de Navarra and CIBEREHD, Pamplona-Madrid, Spain                                                            |              |
| 15:10 - 15:20        | <b>Invited discussant 1 LBA to be announced and 1480</b>                                                                                                                                                                                                                                                                                                                        |              |
| 15:20 - 15:30        | <b>Q&amp;A</b>                                                                                                                                                                                                                                                                                                                                                                  |              |
| <b>15:30 - 16:30</b> | <b>Type: Poster Display session</b><br><b>Title: Poster display session and coffee break</b>                                                                                                                                                                                                                                                                                    | <b>Foyer</b> |
| 15:30 - 15:30        | <b>210P - KINETICS: Real-world study of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) according to Ki67 proliferation index (Ki67)</b><br><u>Timon Vandamme</u> , Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium               |              |
| 15:30 - 15:30        | <b>211P - Retrospective analysis of liver transplantation eligibility based on the Milan criteria in patients with gastroenteropancreatic neuroendocrine tumors</b><br><u>Manon Verhé</u> , University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium                                                                                                                  |              |
| 15:30 - 15:30        | <b>212P - Gastrointestinal Neuroendocrine Tumors in early onset patient: a retrospective study in an ENETS excellence centre</b><br><u>Laura Baldini</u> , Sapienza - Università di Roma, Rome, Italy                                                                                                                                                                           |              |
| 15:30 - 15:30        | <b>213P - Anti-angiogenics combined with chemotherapy improve survival in the first-line treatment of patients with metastatic small bowel adenocarcinoma: a retrospective study by the AGEO.</b><br><u>Emeric Boisteau</u> , CHU de Rennes - Hopital Pontchaillou, Rennes, France                                                                                              |              |



- 15:30 - 15:30      **214P - National Insights into Epidemiological Trends and Outcomes of Malignant Neoplasms of the Small Intestine: A Big Data Analysis**  
Jin-Oh Kim, Soonchunhyang University College of Medicine, Seoul, Republic of Korea
- 15:30 - 15:30      **215P - Sunitinib in Chinese patients with advanced gastrointestinal stromal tumor after failure of imatinib: A multicenter retrospective study**  
Jun Mao, West China Hospital of Sichuan University, Chengdu, China
- 15:30 - 15:30      **216P - Survival Outcomes in Basaloid Squamous Cell Carcinoma of the Anorectal Region: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis**  
Janani Arunachalam, UConn Health - University of Connecticut, Farmington, United States of America
- 15:30 - 15:30      **217eP - Prognostic Role of Ki-67 in Advanced GEP-NET G2: A Retrospective Analysis with ROC Curve Evaluation**  
Wagner Cruz Diaz, INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
- 15:30 - 15:30      **218eP - Clinical and Molecular Features of Small Bowel Adenocarcinoma: A Single-Center Study**  
Maria Caterina De Grandis, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy
- 15:30 - 15:30      **219eP - Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study**  
Haidong Zhang, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China
- 15:30 - 15:30      **220eP - Gastric versus non-gastric metastatic GIST: Differences in overall survival for Latin American population**  
Oliver Millan, INCAN - Instituto Nacional de Cancerologia, Mexico City, Mexico
- 15:30 - 15:30      **221eTiP - A single blinded, randomised controlled trial to evaluate the non-inferiority of HIPEC with low-dose versus high-dose mitomycin C in the treatment of pseudomyxoma peritonei from perforated epithelial mucinous tumours of the appendix**  
Sean Ewings, University of Southampton, Southampton, United Kingdom
- 15:30 - 15:30      **263P - A Phase 1b Dose Escalation Trial of Gemcitabine and Nab-Paclitaxel in Combination with Lixumistat in Patients with Advanced Pancreatic Cancer (COMBAT-PC)**  
Shubham Pant, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- 15:30 - 15:30      **264P - An Open-Label, Uncontrolled Study of Magrolimab (ONO-7913) and Nivolumab (ONO-4538) in Combination with Standard Modified-FOLFIRINOX Chemotherapy as First-Line Treatment in Patients with Metastatic Pancreatic Cancer**  
Makoto Ueno, Kanagawa Cancer Center, Yokohama, Japan



- 15:30 - 15:30      **265P - CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 24-month follow up and dose characterization from the OPTIMIZE-1 study**  
Aurélien Lambert, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, France
- 15:30 - 15:30      **266P - Antitumor activity and ctDNA changes with Cisplatin intraperitoneal chemotherapy in pancreatic cancer with cancerous ascites: a phase 2 study**  
Heli Gao, Fudan University Shanghai Cancer Center, -- --, China
- 15:30 - 15:30      **267P - Provisional results of immunotherapy combined with LSTA1 plus nab-paclitaxel and gemcitabine for locally advanced pancreatic ductal adenocarcinoma**  
Andrew Dean, Saint John of God Subiaco Hospital, Subiaco, Australia
- 15:30 - 15:30      **268P - Activating immune engagement against pancreatic ductal adenocarcinoma (PDAC): Effect of LSTA-1 and durvalumab on tumour infiltrating lymphocytes (TILs)**  
Alice Talbot, St James's Hospital, Dublin, Ireland
- 15:30 - 15:30      **269P - MR-Guided Adaptive (MRgART) Stereotactic Ablative Radiotherapy (SABR) for Postoperative Recurrent and Oligometastatic Pancreatic Cancer: Early Efficacy and Toxicity Outcomes**  
Chen Wang, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- 15:30 - 15:30      **270P - Propensity Score Matched Analysis of Inoperable Pancreatic Cancer Treated with Ablative Stereotactic MR-Guided Radiotherapy With or Without Subsequent Surgery**  
Roberto Herrera, Miami Cancer Institute, Miami, United States of America
- 15:30 - 15:30      **271P - Real-World Evidence analysis of NALIRIFOX in metastatic pancreatic ductal adenocarcinoma**  
Alexander Friedrich, Medical University of Vienna, Vienna, Austria
- 15:30 - 15:30      **272P - Metastatic pancreatic adenocarcinoma: real-world efficacy of first-line treatment**  
Mélanie Debais, Institut Gustave Roussy, Villejuif, France
- 15:30 - 15:30      **273P - A Retrospective Single-Center Analysis of Treatment Strategies and Real-World Outcomes in Locally Advanced Pancreatic Cancer**  
Judit Sanz Beltran, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 15:30 - 15:30      **274P - 5-FU+Nal-IRI vs FOLFOX/XELOX as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after gemcitabine and nab-paclitaxel (GemNab): A propensity score-matched analysis.**  
Giovanni Trovato, Policlinico Universitario Agostino Gemelli, Rome, Italy





- 15:30 - 15:30      **275P - Second-line nanoliposomal irinotecan plus fluorouracil (NIF) versus fluoropyrimidine-based chemotherapy plus oxaliplatin (OF) after gemcitabine plus nab-paclitaxel in patients with advanced pancreatic cancer patients: efficacy comparison using Real-World Data evidence**  
Jesus Rodriguez Pascual, Instituto Oncologico Vithas, Madrid, Spain
- 15:30 - 15:30      **276P - Sequential chemotherapy with GEMCITABINE and PACLITAXEL After FOLFIRINOX Failure in Metastatic Pancreatic Adenocarcinoma: A Retrospective Monocentric Study**  
Elsa Lafitte, IPC - Institut Paoli-Calmettes, Marseille, France
- 15:30 - 15:30      **277P - Additional High-Intensity Focused Ultrasound (HIFU) Improves Survival in Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy: A Large-Cohort Comparative Study**  
Maria Gonzalez Carmona, UKB - Universitätsklinikum Bonn, Bonn, Germany
- 15:30 - 15:30      **278P - Clinical impact of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: a multicenter retrospective study in Japan**  
Masamichi Hayashi, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 15:30 - 15:30      **279P - Transcriptomic Analysis of Homologous Recombination Repair (HRR) Genes in BRCA1/2 and PALB2 Wild-Type (wt) Metastatic Pancreatic Cancer (mPC) Suggests Potential Platinum Sensitivity**  
Binbin Zheng-Lin, Mayo Clinic Cancer Center, Phoenix, United States of America
- 15:30 - 15:30      **280P - Analysis of treatment outcome in Pancreatic Ductal Adenocarcinoma patients harboring germline Pathogenic Variants in DNA Damage Repair genes**  
Catia Carconi, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy
- 15:30 - 15:30      **281P - KRAS Genomic Landscape and Outcomes in Pancreatic Adenocarcinoma: A Single-Institution Experience**  
Ligia Montero De La Fuente, CCUN - Cancer Center Clinica Universidad de Navarra, Pamplona, Spain
- 15:30 - 15:30      **282P - CDKN2A mutations as prognostic and predictive factor in patients (pts) with metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): a single center study.**  
Antonia Cosmaj, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 15:30 - 15:30      **283P - KRAS mutations as prognostic and predictive factor in patients (pts) with metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): a single center study.**  
Linda Di Francesco, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 15:30 - 15:30      **284P - Molecular landscape of advanced pancreatic cancer: results from NGS testing in real-world clinical practice**  
Mireia Busquets Godall, Universitario Parc Taulí, Sabadell, Spain



- 15:30 - 15:30      **285P - Clonal Hematopoiesis as a Pitfall in Pancreatic Ductal Adenocarcinoma Molecular Profiling**  
Irina Croitoru-Cazacu, Fundeni Clinical Institute, Bucharest, Romania
- 15:30 - 15:30      **286P - Clinical significance of ctDNA conversion during systemic therapy in metastatic pancreatic cancer: Insights from ctDNA-RECIST**  
Mette Steiniche, Aarhus University Hospital, Aarhus N, Denmark
- 15:30 - 15:30      **287P - To Biopsy or Not to Biopsy: A Predictive Model for Liquid Biopsy in Advanced Pancreatic Cancer**  
Fouad Attieh, Saint Joseph University - Faculty of Medicine, Beirut, Lebanon
- 15:30 - 15:30      **288P - Prognostic value and Clinical implication of ctDNA Profiling in metastatic pancreatic ductal adenocarcinoma patients: A Multicenter European Study**  
Lina Candia, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
- 15:30 - 15:30      **289P - Prognostic significance of the systemic inflammation response index (SIRI) and nutritional status in metastatic pancreatic cancer: results from the PANTHEIA-SEOM study**  
Carmen Guillen Ponce, Hospital Universitario Ramon y Cajal, Madrid, Spain
- 15:30 - 15:30      **290P - Impact of the Systemic Inflammation Index (SIRI) and Artificial Intelligence(AI)-based Muscle Mass (FocusedON® software) on Chemotherapy Toxicity and Prognosis in Metastatic Pancreatic Cancer: A Proof-of-concept from the PANTHEIA-Spanish Society of Medical Oncology (SEOM) study group**  
Vilma Pacheco-Barcia, Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain
- 15:30 - 15:30      **291P - The Regulatory Roles of Neutrophils in Pancreatic Ductal Adenocarcinoma**  
Marzoque Khan, Walther-Straub-Institute of Pharmacology and Toxicology, Munich, Germany
- 15:30 - 15:30      **292P - Long Survival in Metastatic Pancreatic Cancer: Clinical and Biological Predictors from a Large Retrospective Cohort**  
Anthony Tarabay, Gustave Roussy - Cancer Campus, Villejuif, France
- 15:30 - 15:30      **293P - NALLONG: Real-World Evidence study and prognosis factors on long-term survivors of metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan: hypothesis-driven subgroups analysis.**  
Makoto Ueno, Kanagawa Cancer Center, Yokohama, Japan
- 15:30 - 15:30      **294P - Prevalence and Prognostic Value of Claudin 18.2 Expression in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma in Germany**  
Peter Wild, Goethe University Frankfurt, Dr. Senckenberg Institutes of Pathology and Human Genetics, University Hospital Frankfurt, Frankfurt am Main, Germany



- 15:30 - 15:30      **295P - Diabetes and Its Association with Survival Patterns in Unresectable Pancreatic Adenocarcinoma: A North African Cohort Study**  
Youssef Ait Takniouine, Mohammed VI University Hospital; Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco
- 15:30 - 15:30      **296P - Optimizing Progression-Free Survival Prediction in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Using a Regimen-Specific Nomogram: Insights from Morocco**  
Hassan Abdelilah Tafenzi, Mohammed VI University Hospital; Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakech, Morocco
- 15:30 - 15:30      **297P - Changes in the microbiome during treatment with chemo-immunotherapy in patients diagnosed with pancreatic ductal adenocarcinoma (PDAC): A prospective study.**  
Olivia Comito, University of Notre Dame Australia, Fremantle, Australia
- 15:30 - 15:30      **298P - The effect of the gut microbiome on tumour response to anti-cancer treatment in patients diagnosed with pancreatic ductal adenocarcinoma (PDAC): A prospective study**  
Maclain Robinson, Saint John of God Subiaco Hospital, Subiaco, Australia
- 15:30 - 15:30      **299P - The role of OnkoTEV, PLR and CA19.9 in predicting thromboembolic events in pancreatic cancer patients – retrospective 5-year analysis in a portuguese center**  
Catarina Fernandes, ULS Matosinhos - Hospital Pedro Hispano EPE - SNS, Senhora da Hora, Portugal
- 15:30 - 15:30      **300P - Clinical, pathological, and genomic biomarkers associated with early recurrence in resected localized pancreatic ductal adenocarcinoma (L-PDAC)**  
Virginia Genovesi, AOU Pisana - Stabilimento di Santa Chiara, Querceta, Italy
- 15:30 - 15:30      **301P - Adjuvant chemotherapy of S-1 plus metformin versus S-1 for radical resection of pancreatic cancer : multicenter randomized phase II trial**  
Masayuki Furukawa, NHO Kyushu Cancer Center, Fukuoka, Japan
- 15:30 - 15:30      **302P - Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer**  
Song Gao, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- 15:30 - 15:30      **303P - Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): a pairwise and network meta-analysis**  
Simone Rota, CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, Italy
- 15:30 - 15:30      **304P - Impact of Neoadjuvant and Adjuvant Strategies on Outcomes in Non Metastatic Pancreatic Cancer**  
Sarah Blanchet-Deverly, Université Paris Cité, Paris, France



- 15:30 - 15:30      **305P - Real-World Outcomes in Borderline Resectable Pancreatic Cancer: A Retrospective Cohort from a Multidisciplinary Center in Argentina.**  
Luis Basbus, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- 15:30 - 15:30      **306P - Perioperative and Oncological Outcomes of Laparoscopic Versus Open Pancreaticoduodenectomy: A Meta-Analysis of Randomized Controlled Trials**  
Israa Qutob, Alexandria University, Alexandria, Egypt
- 15:30 - 15:30      **307P - AI-driven patient screening for clinical trials in pancreatic cancer: integrating LLMs with tumor board meetings**  
Arthur Claessens, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, France
- 15:30 - 15:30      **308P - Solid Pseudopapillary Neoplasms of Pancreas**  
Pavel Markov, National Medical Research Center of Surgery named after A.V.Vishnevsky, Moscow, Russian Federation
- 15:30 - 15:30      **309P - Incidence and Clinical features of Pancreatic Cancer in patients with Chronic Calcific Pancreatitis**  
Abul Hussain M., KIMS - Kerala Institute of Medical Sciences - Trivandrum, Thiruvananthapuram, Kerala, India
- 15:30 - 15:30      **310P - Cascade testing in families with hereditary pancreatic cancer.**  
Estrella Varga Lopez, Hospital Universitario de Navarra, Pamplona, Spain
- 15:30 - 15:30      **311P - Effectiveness of Tumor Treating Fields (TTFields) together with gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC) preclinical models**  
Janin Knop, Novocure GmbH, Baar, Switzerland
- 15:30 - 15:30      **312P - GPCR1 as a Selective Target in Pancreatic Cancer: Preclinical Efficacy and Safety of First-in-Class SKM104-MA-L2, a Topoisomerase-Based Antibody-Drug Conjugate with High Therapeutic Index**  
Manel Merabet, Skymab Biotherapeutics, Tours, France
- 15:30 - 15:30      **313P - ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancer**  
Yalu Zhang, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China
- 15:30 - 15:30      **314P - Evaluating Efficacy of Fc-enhanced CTLA-4 Inhibitor Botensilimab, Bastilimab with or without CXCR4 Inhibitor (BL-8040) in an Orthotopic Murine Model**  
Jonathan Lee, New York-Presbyterian Weill Cornell, New York City, United States of America



- 15:30 - 15:30      **315P - Targeted inhibition of exportin-1 enhances anticancer efficacy and augments therapeutic outcomes in pancreatic ductal adenocarcinoma by modulation of LAMC2/KRAS/ERK1/2/AKT signaling network via hsa-miR-193b-3p**  
Aishwarya Singh, Amity University, Uttar Pradesh, Noida, India
- 15:30 - 15:30      **316P - Pancreatic cancer cells are sensitized to FOLFIRINOX treatment by co-application with Tumor Treating Fields (TTFields)**  
Hila Ene, Novocure Ltd, Haifa, Israel
- 15:30 - 15:30      **317P - Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity.**  
Chiao-Min Lin, National Tsing Hua University, Hsinchu City, Taiwan
- 15:30 - 15:30      **318P - Overexpression of SNHG10 lncRNA promotes pancreatic cancer growth through miRNA-150-5p/VEGFA/EGFR/AKT signaling**  
Gouri Pandya, Amity University, Uttar Pradesh, Noida, India
- 15:30 - 15:30      **319P - Antitumour Activity and Safety of First-Line Zanidatamab + Cisplatin-Gemcitabine in Patients with HER2-expressing Biliary Tract Cancer (BTC)**  
Do-Youn Oh, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
- 15:30 - 15:30      **320P - First-line therapy (1L) of cisplatin/gemcitabine (CisGem) with pembrolizumab (Pembro) in patients with advanced biliary tract cancer (aBTC): Open-label, single-arm phase II EORTC-1607-GITCG/ABC-09 Intergroup Study with translational research (TR)**  
Markus Moehler, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
- 15:30 - 15:30      **321P - Results of an Open-Label, Single Arm Phase II Trial Investigating the Efficacy and Safety of Trifluridine/Tipiracil Combined with Irinotecan as a Second Line Therapy in patients with Cholangiocarcinoma (TRITICC)**  
Christoph Roderburg, UKD - Universitätsklinikum Düsseldorf, Düsseldorf, Germany
- 15:30 - 15:30      **322P - Ivosidenib in Pretreated Japanese (JPN) Patients (Pts) With Mutant Isocitrate Dehydrogenase 1 (mIDH1) Nonresectable/Metastatic Cholangiocarcinoma (n/mCCA): Phase 2 Study Results**  
Tomoyuki Satake, National Cancer Center Hospital East, Kashiwa, Japan
- 15:30 - 15:30      **323P - Early safety and efficacy from the Phase 3b TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC)**  
Do-Youn Oh, Seoul National University Hospital; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- 15:30 - 15:30      **324P - Biliary Tract Carcinoma: Real-World Evidence in a Developing Country**  
Mauricio Lema, Clinica de Oncología Astorga, Medellin, Colombia



- 15:30 - 15:30      **325P - Epidemiological profile of biliary tract cancer (BTC) in Argentina. A real-world study by Latin American Intergruop of Gastrointestinal Oncology (ILOGI)**  
Ana Carolina Ituarte, Pablo Soria Hospital, San Salvador De Jujuy, Argentina
- 15:30 - 15:30      **326P - The journey of patients (pts) with biliary tract cancers (BTCs): identifying challenges and unmet needs**  
Salvatore Corallo, University of Pavia, Pavia, Italy
- 15:30 - 15:30      **327P - Real world evidence of outcomes and treatment patterns for advanced biliary tract cancer in Saudi Arabia**  
Kanan Alshammari, Ministry of National Guard for Health Affairs, Riyadh, Saudi Arabia
- 15:30 - 15:30      **328P - Time toxicity (TT) associated with first-line treatment (1L) in patients (pts) with advanced biliary tract cancer (aBTC)**  
Naohiro Okano, Mayo Clinic, Phoenix, United States of America
- 15:30 - 15:30      **329P - First-line maintenance chemotherapy in patients with advanced pancreatic adenocarcinoma: a referral center monocentric cohort.**  
Linda Bartalini, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Pisa, Italy
- 15:30 - 15:30      **330P - Real-world treatment (tx) outcomes of durvalumab (D)-based regimens in advanced biliary tract cancer (aBTC): LIVER-R interim analysis (IA)**  
Andrea Casadei Gardini, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy
- 15:30 - 15:30      **331P - Experience of Durvalumab in unresectable advanced or metastatic biliary tract cancer: a Multicenter Study in Portugal**  
Rafael Fangueiro Marques, CHEDV - Centro Hospitalar de Entre o Douro e Vouga EPE-SNS, Santa Maria da Feira, Portugal
- 15:30 - 15:30      **332P - Impact of Chemoimmunotherapy (CIO) vs. Chemotherapy (CT) Alone in Patients with HRD-Positive and HRD-Negative Biliary Tract Cancers (BTC): A Multicenter Retrospective Survival Analysis**  
Oluseyi Abidoye, Mayo Clinic Cancer Center, Phoenix, United States of America
- 15:30 - 15:30      **333P - Real-world efficacy and toxicity data of Durvalumab plus chemotherapy compared with chemotherapy in patients with Advanced Biliary Tract Cancer: A Retrospective Cohort at the National Cancer Institute in Mexico**  
Lorena Lagarde Nube, INCAN - Instituto Nacional de Cancerologia, CDMX, Mexico
- 15:30 - 15:30      **334P - Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine and durvalumab: A large real-life worldwide population**  
Federica Lo Prinzi, Policlinico Universitario Campus Bio-Medico, Rome, Italy



- 15:30 - 15:30     **335P - Real world study of immunotherapy and Trastuzumab for her2 positive biliary tract cancers**  
Vamshi Krishna Muddu, AIG HOSPITALS HYDERABAD, Hyderabad, India
- 15:30 - 15:30     **336P - The use of regorafenib in cholangiocarcinoma. A real-world data (RWD) review**  
Riona Browne, University College London Hospitals, London, United Kingdom
- 15:30 - 15:30     **337P - Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights from a Multicenter Real-World Study**  
Andrea Casadei Gardini, UniSR - Università Vita e Salute San Raffaele Milano, Milan, Italy
- 15:30 - 15:30     **338P - Interim report of the real-world data analysis of pemigatinib therapy for unresectable or recurrent biliary tract cancer patients in Japan with FGFR2 fusion or FGFR2 rearrangement (JON2303 B)**  
Yuta Kimura, Yamaguchi University Graduate School of Medicine., Ube, Japan
- 15:30 - 15:30     **339P - Treatment of Cholangiocarcinomas: Beyond Second-Line Therapy**  
Anamaria Mihele, Institut Gustave Roussy, Villejuif, France
- 15:30 - 15:30     **340P - Preliminary report on advanced biliary cancer receiving multimodality treatment in the immunotherapy era: a real-world multicenter experience**  
Alessandro Passardi, University Hospital of Modena, Modena, Italy
- 15:30 - 15:30     **341P - Angiotensin system inhibitors use and its impact on survival in cholangiocarcinoma patients**  
Jiyoung Keum, Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea
- 15:30 - 15:30     **342P - Multiomic characterization of early and metastatic biliary tract cancer (BTC)**  
Nakul Shah, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- 15:30 - 15:30     **343P - Body Mass Index and Somatic Variants in Biliary Tract Cancers**  
Layal Al Mahmasani, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America
- 15:30 - 15:30     **344P - Patient characteristics, molecular testing, and treatment patterns of patients with cholangiocarcinoma in the United States: focus on mIDH1 patients**  
Lorenza Rimassa, Humanitas University, Pieve Emanuele and Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, (Milan), Italy
- 15:30 - 15:30     **345P - A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab**  
Mara Persano, UniSR - Università Vita e Salute San Raffaele Milano, Milan, Italy
- 15:30 - 15:30     **346P - Revealing biomarkers of response to chemo-immunotherapy in biliary tract cancer**  
Rita Balsano, Humanitas University, Pieve Emanuele, Italy



- 15:30 - 15:30      **347P - Liquid biopsy for longitudinal molecular characterization of patients (pts) with biliary tract cancer (BTC)**  
Giulia Tesini, Humanitas University and School of Cancer Sciences, University of Glasgow, Pieve Emanuele, Italy
- 15:30 - 15:30      **348P - Molecular profiling success in advanced cholangiocarcinoma (CCA) based on tumour acquisition method.**  
Eleni Vrana, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 15:30 - 15:30      **349P - Exploring the landscape of DNA damage repair genes alterations in biliary tract cancer (BTC): a retrospective, single-center analysis**  
Elena Valenzi, Humanitas University, Pieve Emanuele, Italy
- 15:30 - 15:30      **350P - IDH2-Mutated Cholangiocarcinoma: A Case Series Highlighting Challenges and Insights**  
Layal Al Mahmasani, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America
- 15:30 - 15:30      **351P - Comprehensive genomic profiling and efficacy data in patients with advanced biliary tract cancer treated in 1st line with chemo-immunotherapy combination: a real world experience**  
Valeria Nacca, ASL Caserta, P.O. Piedimonte Matese, caserta, Italy
- 15:30 - 15:30      **352P - Characterization of cholangiocarcinoma tumor microenvironment at spatial resolution identifies two main multicellular communities**  
Mar Teixido, Arnau de Vilanova University Hospital - IRBLleida, Lleida, Spain
- 15:30 - 15:30      **353P - Prognostic role of metastatic sites in a worldwide population of patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab.**  
Silvia Camera, IRCCS Ospedale San Raffaele, Milan, Italy
- 15:30 - 15:30      **354P - High Serum Ferritin Level is Prognostic for Progression-Free and Overall Survival as a Potential Biomarker in Patients with Advanced Biliary Tract Cancer**  
Erman Akkus, Ankara University Faculty of Medicine, Ankara, Türkiye
- 15:30 - 15:30      **355P - Machine Learning vs. Conventional Approaches: A Comparative Analysis for Intrahepatic Cholangiocarcinoma Recurrence Prediction**  
Ruoyu Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China
- 15:30 - 15:30      **356P - CD80 tumour-expression predicts benefits from capecitabine in the BILCAP phase III randomized adjuvant trial**  
Michela Rofei, Tor Vergata University Hospital, University of Glasgow, Rome, Glasgow, Italy





- 15:30 - 15:30     **357P - ADJUBIL - A Phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUVant BILiary tract cancer – the IKF/AIO-ADJUBIL trial**  
Thorsten Goetze, Krankenhaus Nordwest, University Cancer Center Frankfurt and Frankfurter Institut für Klinische Krebsforschung IKF GmbH, Frankfurt am Main, Germany
- 15:30 - 15:30     **358P - Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study**  
Wen-Ying Lin, Taipei Veterans General Hospital, Taipei City, Taiwan
- 15:30 - 15:30     **359P - The role of arginase 2 in the nerve innervation of cholangiocarcinoma**  
Yulin Cheng, Soochow University Dushuhu Campus, Suzhou, China
- 15:30 - 15:30     **360P - MTAP Loss in Pancreatobiliary Cancers: Insights into Co-occurring Genetic Alterations**  
Wagner Cruz Diaz, Fundación Jiménez Díaz University Hospital, Madrid, Spain
- 15:30 - 15:30     **361P - Treatment patterns and survival outcomes of patients with gallbladder cancer (GBC): a real-world comparative study over two decades**  
Maria Pia Quitadamo, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, Italy
- 15:30 - 15:30     **362P - Role of Limited NGS in Gallbladder Cancer in LMIC: A Real-World data of Genomic Profile and Survival Outcomes**  
Reetu Singhal, IMS & SUM Hospital, Bhubaneswar, India
- 15:30 - 15:30     **363P - HER-2 neu expression in Gallbladder Cancer: A Real-World Study on Molecular Alterations and Targeted Therapy Response**  
Reetu Singhal, IMS & SUM Hospital, Bhubaneswar, India
- 15:30 - 15:30     **364P - CHST4 and Its Contribution to Gallbladder Cancer Susceptibility: Mucin Expression Modulation via Keratan Sulfate Pathways**  
Deeptima Jaiswar, National Institute of Science Education and Research Bhubaneswar (NISER), Jatni, India
- 15:30 - 15:30     **365P - Quantitative Evaluation of Contrast Enhanced Harmonic Endoscopic Ultrasound in Periapillary Duodenal Lesions**  
Yuting Qiu, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China
- 15:30 - 15:30     **366eP - Efficacy and Safety of Camrelizumab Combined with Chemotherapy in the Treatment of Advanced Pancreatic Cancer: A Clinical Trial**  
Yu Wang, Shandong First Medical University Affiliated Provincial Hospital, Jinan, China
- 15:30 - 15:30     **367eP - Phase II trial of FTD/TPI and nal-IRI in Advanced PDAC**  
Lindsay Hannan, Emory University, Atlanta, United States of America



- 15:30 - 15:30      **368eP - Real-World Outcomes of Nanoliposomal Irinotecan Plus Fluorouracil in Second-Line Treatment of Advanced Pancreatic Cancer: A Multicenter Retrospective Study from Thailand**  
Tawasapon Thambamroong, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
- 15:30 - 15:30      **369eP - Impact of ascites on treatment outcomes of Nal-IRI+5-FU/LV in patients with pancreatic cancer with peritoneal dissemination**  
Kanae Inoue, National Cancer Center Hospital East, Kashiwa, Japan
- 15:30 - 15:30      **370eP - Prognostic significance of CA19-9 before conversion surgery for patients with initially unresectable pancreatic cancer**  
Satoshi Kobayashi, Kanagawa Cancer Center, Yokohama, Japan
- 15:30 - 15:30      **371eP - Distinct microbiome composition and reduced interactions in patients with pancreatic cancer**  
WootaeK Seo, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
- 15:30 - 15:30      **372eP - Molecular Determinants of Survival in Pancreatic Adenocarcinoma: A Weighted gene co-expression network analysis**  
Jaber Jaradat, Mutah University, Al-Karak, Jordan
- 15:30 - 15:30      **373eP - The role of radiotherapy in pancreatic cancer: retrospective analysis of a tertiary center**  
Ana Ferrão, HSM - Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon, Portugal
- 15:30 - 15:30      **374eP - Effects of perioperative exercise therapy in patients with pancreatic cancer: A systematic review and meta-analysis**  
Naoko Sato, Fukushima Medical University, Fukushima, Japan
- 15:30 - 15:30      **375eP - Biliary Stenting in Biliopancreatic Tumors: Evidence from Real-World practice**  
Luca Pratesi, University of Florence, Florence, Italy
- 15:30 - 15:30      **376eP - Endoscopic vs Percutaneous Biliary Decompression in Malignant Jaundice: Impact on Postoperative Complications and Hospital Stay.**  
M Manukyan, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation
- 15:30 - 15:30      **377eP - Advanced and metastatic biliary tract cancer: Real-world evidence from a single institution in Argentina.**  
Pilar Fernandez, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- 15:30 - 15:30      **378eP - Pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an initial analysis of real-world experience.**  
Mitsuhiro Sasaki, National Cancer Center Hospital East, Kashiwa, Japan



- 15:30 - 15:30      **379eP - Real-world outcomes of second-line chemotherapy in biliary tract cancer following chemo-immunotherapy: insights from a single italian institute**  
Emanuela Di Giacomo, Policlinico Universitario Campus Bio-Medico, Rome, Italy
- 15:30 - 15:30      **380eP - Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: a systematic review and meta-analysis**  
Natalia Tissera, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
- 15:30 - 15:30      **381eP - Trace elements in serum as potential biomarkers in biliary tract cancers**  
Martina Rebersek, Institute of Oncology Ljubljana, Ljubljana, Slovenia
- 15:30 - 15:30      **382eP - Bile microbiome analysis in patients with biliary tract cancer**  
Dong Kee Jang, Boramae Medical Center, Seoul, Republic of Korea
- 15:30 - 15:30      **383eP - Accuracy under Pressure : Evaluating Gallbladder Frozen Sections Compared to Final Histopathology Report in a Tertiary Care Hospital**  
Rukmini Bezbaruah, Dr. B. Borooah Cancer Institute, Guwahati, India
- 15:30 - 15:30      **384TiP - Quemliclustat and Chemotherapy in Previously Untreated Patients With Metastatic Pancreatic Ductal Adenocarcinoma: PRISM-1, a Randomized, Placebo-Controlled, Phase 3 Trial**  
Teresa Macarulla Mercade, Vall d'Hebron University Hospital, Barcelona, Spain
- 15:30 - 15:30      **385TiP - AZD0901 monotherapy in patients (pts) with advanced biliary tract cancer (BTC) expressing Claudin18.2 (CLDN18.2): CLARITY-PanTumour01 Substudy 3**  
Lipika Goyal, Stanford Cancer Center, Stanford School of Medicine, Stanford, United States of America
- 15:30 - 15:30      **386TiP - Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: the phase III PANThEON trial**  
Carolina Sciortino, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
- 15:30 - 15:30      **387eTiP - DOVIPA: A Phase II Study with Safety Run-In of mFOLFIRINOX, Dostarlimab, and Oral Vitamin D in Metastatic Pancreatic Cancer with Translational Research on Resistance Mechanisms**  
Asmahane Teillet Benmaziane, Hopital Foch, Suresnes, France
- 15:30 - 15:30      **394P - Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials**  
Hui Yan Luo, Sun Yat-Sen University Cancer Center, Guangzhou, China



- 15:30 - 15:30      **395P - RATIONALE-306 subgroup analysis of patients (pts) with advanced/metastatic esophageal squamous cell cancer (ESCC) and Tumor Area Positivity (TAP) score  $\geq$ 5%**  
David Tougeron, CHU Poitiers - Jean Bernard Hôpital, Poitiers, France
- 15:30 - 15:30      **396P - A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy**  
Hung-Yang Kuo, National Taiwan University Hospital, Taipei City, Taiwan
- 15:30 - 15:30      **397P - Definition and treatment of oligometastatic esophageal squamous cell carcinoma according to multidisciplinary tumor boards in Japan: OMESC-2 study**  
Motoo Nomura, Kyoto University Hospital, Kyoto, Japan
- 15:30 - 15:30      **398P - Efficacy and safety of radiation therapy alone in patients with stage II/III esophageal squamous cell carcinoma intolerant of chemotherapy and surgery a multi-center retrospective study**  
Takako Yoshii, Saitama Prefectural Cancer Center, Ina, Japan
- 15:30 - 15:30      **399P - ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1-Mediated Metabolic Reprogramming**  
Xinyue Ma, Qilu Hospital of Shandong University, Jinan, China
- 15:30 - 15:30      **400P - Real world data of different neoadjuvant chemoradiotherapy regimens in locally advanced esophageal cancer**  
Laia Casas Jurado, Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Hospitalet de Llobregat, Spain
- 15:30 - 15:30      **401P - Neoadjuvant Chemo-Radiotherapy In Older Patients with Oesophageal Cancer**  
Michele Aquilano, AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
- 15:30 - 15:30      **402P - Impact of larger tumor lengths on survival in esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: Real-World outcomes**  
Samir Batham, HCG Aastha Cancer Centre, Ahmedabad, India
- 15:30 - 15:30      **403P - Clinical utility of primary prophylactic filgrastim in resectable esophageal cancer treated with neoadjuvant FLOT therapy.**  
Junko Tauchi, National Cancer Center Hospital, Chuo-ku, Japan
- 15:30 - 15:30      **404P - MRD analysis following curative intent treatment in patients with locally advanced esophageal cancer utilizing MAESTRO, an ultrasensitive ctDNA assay**  
Anuj Patel, Dana-Farber Cancer Institute, Boston, United States of America
- 15:30 - 15:30      **405P - DKN-01 and atezolizumab as second or third-line therapy in advanced mismatch repair proficient (MMRp) oesophagogastric adenocarcinoma (OGA): WAKING trial**  
Anderley Gordon, The Royal Marsden Hospital, Sutton, United Kingdom



- 15:30 - 15:30      **406P - Real-life use of docetaxel, cisplatin and 5-FU (DCFm) combined with nivolumab in advanced gastroesophageal cancers: the TRINIGAST observational study**  
Arthur Bauer, CHU de Clermont-Ferrand - Site Estaing, Clermont-Ferrand, France
- 15:30 - 15:30      **407P - Immune Composition Based Efficacy Assessment of 1st-line Immune-chemotherapy Combinations in Gastroesophageal Cancer: Subgroup Analysis of the Phase II IKF-AIO-STO-0417 / Moonlight Trial**  
Michael Masetti, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, Germany
- 15:30 - 15:30      **408P - Claudin18.2 expression and its association with immunotherapy outcomes in gastroesophageal adenocarcinoma**  
Eduardo Terán Brage, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain
- 15:30 - 15:30      **409P - Prognostic factors associated with survival for patients with HER2+ GEA**  
John Bridgewater, UCL Cancer Institute, UCL, London, United Kingdom
- 15:30 - 15:30      **410P - Comprehensive molecular and immunological characterization of CLDN18.2 in Esophageal and Esophagogastric Junction Carcinoma (EEJC)**  
Midhun Malla, University of Alabama at Birmingham, Birmingham, United States of America
- 15:30 - 15:30      **411P - Molecular characterization of esophagogastric adenocarcinoma: prognostic and predictive impact of MSI and MSS tumors**  
Juan Luis Catoya-Villa, Hospital Universitario 12 de Octubre, Madrid, Spain
- 15:30 - 15:30      **412P - Tumour-free Lymph Node Microarchitecture Associates with Tumour Location Specific Survival in Oesophagogastric Cancer – Results from the OE05 and ST03 trials**  
Elzbieta Budginaite, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
- 15:30 - 15:30      **413P - Mismatch Repair Deficiency (MMRd) in Esophagogastric Adenocarcinoma (ADC) following Chemotherapy for Resectable Disease: Correlation with Survival and Recurrence Patterns from ST03 and OE05 Trials**  
Panagiotis Ntellas, The Royal Marsden Hospital, London, United Kingdom
- 15:30 - 15:30      **414P - Correlation between tumor regression grades (TRG) and overall survival in locally advanced resectable gastroesophageal adenocarcinoma (LAR-GEA): real world data (RWD) analysis**  
Laura Gonzalez-Aguado, Hospital Clinic of Barcelona, Barcelona, Spain
- 15:30 - 15:30      **415P - Comprehensive Nutritional Assessment in Patients with Locally Advanced Gastroesophageal Adenocarcinoma in the Perioperative Setting: A Subanalysis of a Prospective Observational Study**  
Laura Boldrini, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy



- 15:30 - 15:30      **416P - The Shifting Global Landscape of Interventional Clinical Trials in Gastric and Gastroesophageal Cancers: A ClinicalTrials.gov Analysis**  
Amalya Sargsyan, Yeolyan Hematology and Oncology Center/Immune Oncology Research Insititute, Yerevan, Armenia
- 15:30 - 15:30      **417P - Comparative efficacy and safety of tislelizumab (TIS) vs other anti-PD-1 treatments in first-line (1L) gastric or gastroesophageal junction cancer (GC/GEJC): a network meta-analysis (NMA)**  
Maria Alsina Maqueda, Hospital Universitario de Navarra, Pamplona, Spain
- 15:30 - 15:30      **418P - Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study**  
Hong Qiu, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 15:30 - 15:30      **419P - Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)**  
Rongrui Liu, Chinese PLA General Hospital (301 Military Hospital), Beijing, China
- 15:30 - 15:30      **420P - Impact of Early Tumor Shrinkage as a Prognostic Predictor in Patients Treated with First-Line Nivolumab Plus Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Multi-Center Retrospective Study in Japan**  
Rin Inamoto, Saitama Cancer Center, Ina, Japan
- 15:30 - 15:30      **421P - Prognostic impact of the modified Glasgow Prognostic Score in advanced gastric and gastroesophageal junction cancer treated with first-line nivolumab plus chemotherapy: a multi-center retrospective study.**  
Nozomu Ogura, NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, Japan
- 15:30 - 15:30      **422P - Perioperative FLOT in Resectable Gastric and GEJ Cancer: Real-Life Experience and Prognostic Insights**  
Ina Valeria Zurlo, Ospedale Vito Fazzi - ASL Lecce, Lecce, Italy
- 15:30 - 15:30      **423P - Pathological Complete Response Rates with perioperative FLOT chemotherapy in Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis from Eastern India**  
Ishita Rastogi, AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, India
- 15:30 - 15:30      **424P - Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study**  
Muxing Kang, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
- 15:30 - 15:30      **425P - Real-World Treatment Patterns and Outcomes in Patients with Advanced Gastric Cancer in Japan**  
Hisato Kawakami, Tohoku University Graduate School of Medicine, Sendai, Japan



- 15:30 - 15:30      **426P - The Strategy of Planned Discontinuation of Oxaliplatin for Advanced Gastric Cancer Treated with Nivolumab plus Chemotherapy: A Multi-center Retrospective Study**  
Mitsuhiro Furuta, Kanagawa Cancer Center, Yokohama, Japan
- 15:30 - 15:30      **427P - Safety and efficacy of nivolumab plus chemotherapy in patients with advanced gastric cancer with ascites: a multi-center retrospective study in Japan**  
Misa Onishi, Kanagawa Cancer Center, Yokohama, Japan
- 15:30 - 15:30      **428P - Effectiveness of first-line regimen reintroduction in the second-line setting for advanced gastric cancer**  
Rukiyat Abdulaeva, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation
- 15:30 - 15:30      **429P - Prognostic Significance of HER2-Low Status in Advanced Gastric Cancer**  
Beliz Karaoglan, Ankara University Faculty of Medicine, Ankara, Türkiye
- 15:30 - 15:30      **430P - Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical Trial**  
Haoxin Peng, Peking University Cancer Hospital & Institute, Beijing, China
- 15:30 - 15:30      **431P - High Amphiregulin (AREG) plasma levels are associated with shorter survival in patients with advanced gastric cancer but are not predictive for response to Cetuximab in combination with first line chemotherapy in the global EXPAND phase III trial**  
Benjamin Kobitzsch, University of Leipzig Medical Center, Leipzig, Germany
- 15:30 - 15:30      **432P - Metastatic Patterns And Inflammatory Biomarkers: Predicting Outcomes In Gastric Cancer**  
Diana Rubio, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico
- 15:30 - 15:30      **433P - Somatic BREast Cancer (BRCA) mutations in HER2 negative advanced gastric adenocarcinomas (AGC)**  
Amrit Dhar, Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, India
- 15:30 - 15:30      **434P - Deep Learning-Based CT Segmentation Methods for Radiomics in Pembrolizumab-Treated Gastric Cancer**  
Taewon Han, Samsung Medical Center (SMC), Seoul, Republic of Korea
- 15:30 - 15:30      **435P - Conversion Surgery in Metastatic Gastric Cancer: A Retrospective Analysis**  
Daria Gavrilova, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation
- 15:30 - 15:30      **436P - Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions**  
Yun Feng, Fudan University Shanghai Cancer Center, Shanghai, China



- 15:30 - 15:30      **437P - Distinct tumor microenvironment composition of early onset gastric cancer peritoneal metastases**  
Raghav Sundar, Yale School of Medicine, New Haven, United States of America
- 15:30 - 15:30      **438P - Young Onset Gastric Adenocarcinoma: A Population-Based Analysis**  
Oana Deac, Trinity College Dublin, Dublin, Ireland
- 15:30 - 15:30      **439P - Clinicopathological features, molecular profiling and survival outcomes in young-onset gastric cancer: a retrospective cohort study**  
Coral García De Quevedo Suero, Hospital Universitario Ramon y Cajal, Madrid, Spain
- 15:30 - 15:30      **440P - Evaluation of recurrence patterns in patients treated with FLOT regimen**  
Diogo Lopes, Hospital de Braga EPE - SNS, Braga, Portugal
- 15:30 - 15:30      **441P - Long-term quality of life after distal and pylorus-preserving gastrectomy for stage I gastric cancer: A prospective multi-institutional study (CCOG1601)**  
Chie Tanaka, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 15:30 - 15:30      **442P - Urinary Retention After Minimally Invasive Gastrectomy: Is Routine Preoperative Catheterization Justified?**  
Daye Ahn, Jeonbuk National University Hospital, Jeonju, Republic of Korea
- 15:30 - 15:30      **443P - HSF2 upregulates viral oncogenes by altering the epigenetic landscape at key viral promoter in EBVaGC.**  
Lorenza Cutrone, Abo Akademi University, Turku, Finland
- 15:30 - 15:30      **444P - Gastric Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, Biometrics and Modeling of Alive Supersystems for Best Management.**  
Oleg Kshivets, Bagrationovsk Hospital, Bagrationovsk, Russian Federation
- 15:30 - 15:30      **445P - (68)Ga-FAPI PET/CT demonstrates diagnostic value for detecting subtle metastatic lesions and prognostic value for neoadjuvant immunochemotherapy in locally advanced gastric cancer**  
Yihui Han, West China Hospital of Sichuan University, Chengdu, China
- 15:30 - 15:30      **446P - Detection of gastric cancer using DNA remnants in red blood cells**  
Yuehua Han, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 15:30 - 15:30      **447P - Screening strategy in the study of genetic variants associated with Gastric Cancer in Tunisian patients**  
Jihenne Ben Aissa Haj, IPT - Institut Pasteur de Tunis, Tunis, Tunisia
- 15:30 - 15:30      **448P - Spatial and quantitative expression of Toll-like receptors (TLRs) 4, 5 and 9 in gastric premalignant lesions in presence and absence of Helicobacter pylori**  
Franz Villarroel-Espindola, FALP - Fundacion Arturo Lopez Perez, Providencia, Chile





- 15:30 - 15:30      **449P - Metagenomic Sequencing Reveals Gastric Microbiome Dysbiosis Patterns Between Gastric Cancer and Chronic Gastritis in the Indian Subcontinent: A Multi-Center Study**  
Vigneshwar Suriya Prakash Sinnarsan, JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
- 15:30 - 15:30      **450P - Association between Metabolic Score for Insulin Resistance and the Incidence of Gastric Cancer in South Korea: A Nationwide Population-based Study**  
Jong Yoon Lee, Dong-A University College of Medicine, Busan, Republic of Korea, Republic of Korea
- 15:30 - 15:30      **451P - Socioeconomic and clinical determinants of quality of life in Moroccan gastric cancer patients.**  
Safaa Kriouile, National Institute of Oncology, Rabat, Morocco
- 15:30 - 15:30      **452P - Neoadjuvant chemotherapy in gastric adenocarcinoma: Challenges to overcome in Latin American population**  
German Calderillo Ruiz, INCAN - Instituto Nacional de Cancerologia, Mexico City, Mexico
- 15:30 - 15:30      **453P - Real-world (RW) evidence in gastric and esophageal cancer: first results of patients (pts) treated with nivolumab (NIVO) plus chemotherapy (chemo) from the noninterventional INGA study in Germany**  
Alexander Stein, Hämatologisch-Onkologische Praxis Eppendorf Universitäres, Hamburg, Germany
- 15:30 - 15:30      **454P - Global physician and patient-reported symptom concordance in association with quality of life in HER2-negative advanced gastric, gastroesophageal or esophageal adenocarcinoma**  
Florian Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, Germany
- 15:30 - 15:30      **455P - Effects of neighborhood deprivation index on survival in upper gastrointestinal cancers**  
Sarbajit Mukherjee, Miami Cancer Institute, Miami, United States of America
- 15:30 - 15:30      **456P - Mutational Signature Dynamics in Gastric and Esophageal Cancers: A Retrospective Comprehensive Genomic Analysis**  
Nazesh Khan, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, UCCSH, Lübeck, Germany
- 15:30 - 15:30      **457P - Size of the largest nonmetastatic regional lymph node: a validated prognostic marker in patients with esophageal, junctional or gastric adenocarcinoma**  
Maximilian Kloft, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, Netherlands



- 15:30 - 15:30      **458P - Psychological Health as a Mediator between Diet and Upper Gastrointestinal Cancer Risk: Evidence from a Large-scale Population-based Screening Project**  
Yueying Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China
- 15:30 - 15:30      **459P - Artificial Intelligence in Action: A Meta-Analysis of AI-Assisted Endoscopy for Upper GI Cancers**  
Israa Qutob, Alexandria University, Alexandria, Egypt
- 15:30 - 15:30      **460eP - Induction Chemotherapy Followed by Definitive Chemoradiation in Patients With Inoperable Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Study**  
Deniz Can Guven, Hacettepe University Oncology Hospital, Ankara, Türkiye
- 15:30 - 15:30      **461eP - DCF regimen as an alternative to chemoradiotherapy in esophagus squamous cell carcinoma (ESCC).**  
Innara Turkpenova, Kazakh Research Institute of Oncology and Radiology-KazIOR, Almaty, Kazakhstan
- 15:30 - 15:30      **462eP - Correlations between MYH11 expression and clinicopathological characteristics of ESCC patients**  
Fatemeh Alizadeh, OMID Hospital Mashhad University of Medical Sciences, Mashhad, Iran
- 15:30 - 15:30      **463eP - Evaluation of efficacy of Definitive Chemo-radiation in inoperable Carcinoma Esophagus**  
Sujana Vuba, AIG Hospitals, Hyderabad, India
- 15:30 - 15:30      **464eP - Clinical outcomes and predictors of early mortality in patients with oesophageal cancer post-stent insertion**  
Risantini Murugan, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
- 15:30 - 15:30      **465eP - Analysis of the trend in the incidence of cancer of the esophagus in the Republic of Uzbekistan for the last 20 years**  
Abrorjon Yusupbekov, Republican specialised scientific and practical medical center of oncology and radiology, Tashkent, Uzbekistan
- 15:30 - 15:30      **478eTiP - UCCL-IKF-NeoART – An international phase Ib/II trial investigating trastuzumab-deruxtecan (T-DXd) combined with neoadjuvant chemotherapy (Ctx) for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)**  
Gertraud Stocker, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany
- 15:30 - 15:30      **466eP - Real-World Outcomes of Nivolumab-Based Chemoimmunotherapy in Patients with Advanced Gastric Cancer**  
Tae-Hwan Kim, Ajou University School of Medicine, Suwon, Republic of Korea



- 15:30 - 15:30      **467eP - Real-World Outcomes of Nivolumab Plus Chemotherapy in Advanced Gastric Cancer with CPS 1-5: A Single-Center Retrospective Cohort Study from Argentina.**  
Victoria Blanco, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- 15:30 - 15:30      **468eP - Impact of biomarker-guided targeted therapy on survival in advanced gastric adenocarcinoma: a single-center retrospective analysis**  
Carmen Blanco Abad, Hospital Universitario Miguel Servet, Zaragoza, Spain
- 15:30 - 15:30      **469eP - Sarcopenia measured in computed tomography as a prognostic and predictive factor of response to perioperative FLOT regimen chemotherapy in gastric cancer patients**  
Katarzyna Marcisz-Grzanka, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 15:30 - 15:30      **470eP - Expression characteristics and prognostic significance of long non-coding RNA CASC15 in gastric cancer and its association with immune microenvironment and genomic instability**  
Diliyaer Abudukeremu, The Second Hospital of Tianjin Medical University, Tianjin, China
- 15:30 - 15:30      **471eP - Pan-cancer analysis reveals the expression characteristics of MIR181A1HG in gastric adenocarcinoma (STAD) and its association with the immune microenvironment and RNA modification.**  
Peishi Yu, Tianjin Medical University, Tianjin, China
- 15:30 - 15:30      **472eP - Impact of Neoadjuvant Chemotherapy on Nutritional Status and Its Influence on Clinical Outcomes in Resectable Gastric Cancer**  
Diana Rosero Rodriguez, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
- 15:30 - 15:30      **473eP - When the End Comes Too Soon: Adjuvant Chemotherapy Dropout in Gastric Cancer and the Promise of TNT**  
Aitor Uriarte Etxebarria, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
- 15:30 - 15:30      **474eP - Evaluation of nutritional Support Strategies in Metastatic Gastric Cancer Patients Undergoing First-Line treatments**  
Floriana Nappo, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
- 15:30 - 15:30      **475eP - KHSRP promotes cancer stem cell maintenance, tumorigenesis, and suppresses anti-tumor immunity in gastric cancer**  
Zou Lin, Sun Yat-Sen University, Guangzhou, China
- 15:30 - 15:30      **476eP - Global Impact and Value of Disability-Adjusted Life Years from Esophageal and Gastric cancers: A Cancer-Specific Multicountry Analysis (2000–2021)**  
Renato Aste Ruiz, Universidad de Villanueva, Madrid, Spain



- 15:30 - 15:30      **477TiP - A Randomised Phase II Study of Zimberelimab ± Domvanalimab Immunotherapy in Resectable Mismatch Repair Deficient (dMMR) Gastric and Gastroesophageal Junctional (G/GOJ) Adenocarcinoma (ZODIAC)**  
Georgina Keogh, The Royal Marsden Hospital, London, United Kingdom
- 15:30 - 15:30      **480P - DNA remnants in red blood cells enable early detection of gastrointestinal cancers**  
Haobo Sun, Westlake University, Hangzhou, China
- 15:30 - 15:30      **481P - The predictive role of Neutrophil-to-Lymphocyte Ratio in patients with solid cancers treated with immune checkpoint inhibitors – a pooled analysis of seven clinical trials of the German AIO study group**  
Lena Dreikhausen, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
- 15:30 - 15:30      **482P - Comprehensive Genomic Profiling in routine clinical practice: performance and clinical utility for patients with Gastro-Intestinal cancers**  
Giulia Maddalena, IOV - Istituto Oncologico Veneto IRCCS, Padua, Italy
- 15:30 - 15:30      **483P - Safety and efficacy of cisplatin and nab-paclitaxel pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase IB study**  
Thibaud Kössler, HUG - Hopitaux Universitaires de Geneve, Geneva, Switzerland
- 15:30 - 15:30      **484P - Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastases: Insights from a Portuguese Center**  
Maria João Oura, CHUSJ - Centro Hospitalar Sao Joao E.P.E - SNS - Polo Porto, Porto, Portugal
- 15:30 - 15:30      **485P - Ovarian Metastasis from Gastrointestinal Cancers: Clinicopathologic Features, Molecular Profile, and Outcomes, a single centre review in Oman**  
Ahmad Al Ghoche, SULTAN QABOOS CANCER CENTRE - UNIVERSITY MEDICAL CITY, Muscat, Oman
- 15:30 - 15:30      **486P - Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, BA3182, in Pts with Treatment Refractory Metastatic Adenocarcinoma**  
Alexander Starodub, The Christ Hospital - Hematology & Oncology, Cincinnati, United States of America
- 15:30 - 15:30      **487P - Uncharted Territory: Efficacy and Safety of Lower Dose Intensity Immunotherapy in Mismatch-Repair-Deficient and Microsatellite Instability-High Gastrointestinal Cancers: Real World Data**  
Ali Shamseddine, AUBMC - American University of Beirut Medical Center, Beirut, Lebanon
- 15:30 - 15:30      **488P - Exploring the Relationship Between Immunotherapy Toxicity and Treatment Response in dMMR Gastrointestinal Malignancies**  
Julia Freckelton, Royal Marsden Hospital, London, United Kingdom



- 15:30 - 15:30      **489P - Efficacy of immune checkpoint inhibitors in patients with dMMR/MSI-H advanced gastric cancer and metastatic colorectal cancer in clinical practice**  
Shohei Udagawa, The Cancer Institute Hospital of JFCR, Tokyo, Japan
- 15:30 - 15:30      **490P - S1 based chemotherapy in gastrointestinal cancers : a real world experience of efficacy and toxicity from a tertiary cancer centre in India**  
Avinash Bonda, AIG Hospitals, Hyderabad, India
- 15:30 - 15:30      **491P - Zongertinib in HER2-altered gastrointestinal cancers: preclinical activity and clinical findings from a phase Ia study**  
Kiyotaka Yoh, National Cancer Center Hospital East, Kashiwa-shi, Japan
- 15:30 - 15:30      **492P - AI-ML-Assisted Epitope Mapping for Monoclonal Antibodies in Gastrointestinal and Colorectal Cancers**  
Stefano Jaconi, ONK OnlyNoseKnows GmbH, Lugano-Viganello, Switzerland
- 15:30 - 15:30      **493P - Young onset gastrointestinal cancer patients enrolled in Phase I Clinical Trials: the experience from Gustave Roussy Cancer Center**  
Irene Gonzalez Caraballo, Hospital General Universitario Gregorio Marañon, Madrid, Spain
- 15:30 - 15:30      **494P - Preliminary data from the TEOGIC study: a comprehensive characterization of early-onset gastrointestinal cancer in Spain.**  
Ana Elsa Huerta-Hernández, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona-Iruña, Spain
- 15:30 - 15:30      **495P - Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction**  
Wendy Chan, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong SAR, China
- 15:30 - 15:30      **496P - Fertility Preservation Practices at Gastrointestinal (GI) Oncology in Europe: A Pan-European study**  
Irit Ben-Aharon, Rambam Health Care Campus, Haifa, Israel
- 15:30 - 15:30      **497P - Psychological Distress in Caregivers of Gastrointestinal Cancers Patients: A Study of PTSD, Anxiety, and Depression**  
Israa Qutob, Alexandria University, Alexandria, Egypt
- 15:30 - 15:30      **498P - Prevalence of Malnutrition and Its Impact on Hospitalized gastrointestinal cancer patients: Screening Results Conducted at Admission to the Oncology Inpatient Unit**  
Maria Pereira, Unidade Local de Saúde de Braga EPE - SNS, Braga, Portugal
- 15:30 - 15:30      **499P - Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapy**  
Winnie Yeo, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China



- 15:30 - 15:30      **500P - Impact of Chemotherapy-Induced Peripheral Neuropathy in Quality of Life of Patients Treated with Oxaliplatin: a prospective real-world study**  
Marisa Couto, CHUSJ - Centro Hospitalar Sao Joao E.P.E - SNS - Polo Porto, Porto, Portugal
- 15:30 - 15:30      **501P - Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal (GI) adenocarcinoma undergoing systemic treatment.**  
Vicente Valentí, Hospital Santa Tecla, Tarragona, Spain
- 15:30 - 15:30      **502P - Patient-Derived Organoid Models Reveal Variant-Specific Responses and Synergistic Drug Effects in KRAS-Driven Digestive Cancers**  
Gustave Ronteix, Orakl Oncology SAS, Le Kremlin-Bicêtre, France
- 15:30 - 15:30      **503P - Identifying clinical development opportunities for Antibody Drug Conjugates (ADCs) in gastrointestinal (GI) cancers through RNA-expression analysis in 637 cell lines**  
Julia Freckelton, Royal Marsden Hospital, London, United Kingdom
- 15:30 - 15:30      **504eP - Comprehensive genomic profiling (CGP) of gastrointestinal cancers: A single-institution experience**  
Jasna Radic, KBC Sestre Milosrdnice - University Hospital Center, Zagreb, Croatia
- 15:30 - 15:30      **505eP - Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers**  
Jinzhong Chen, Nanfang Hospital, Southern Medical University, Guangzhou, China
- 15:30 - 15:30      **506eP - Impact of CARG-Guided Dose Adjustment of Anticancer Therapy on Adverse Events in Chinese Elderly Cancer Patients: A Prospective Study**  
Yuping Ge, Peking Union Medical College Hospital, Beijing, China
- 15:30 - 15:30      **507eP - Psychological distress and overload prevalence in Latin American caregivers of colorectal cancer**  
Berenice Carbajal-López, INCAN - Instituto Nacional de Cancerología, Ciudad de Mexico, Mexico
- 15:30 - 15:30      **508eP - Gastric partitioning compared to conventional gastrojejunostomy as palliative surgeries in patients with gastric outlet obstruction due to unresectable gastric or pancreatic cancers: a pair-wise and individual patient data meta-analysis.**  
Mohamed Hamouda Elkasaby, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
- 15:30 - 15:30      **509eP - "Evaluating the Efficacy of Atorvastatin in Mitigating Radiotherapy-Induced Gastrointestinal Toxicity: A Randomized Controlled Trial"**  
Mohammadreza Elhaie, Isfahan University of Medical Sciences, Isfahan, Iran
- 15:30 - 15:30      **510eTiP - Consensus for Nutritional Management in Pancreatobiliary and Upper Gastrointestinal Cancer: A Delphi Study**  
Vilma Pacheco-Barcia, Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain



|                      |                                                                                                                                                                    |                       |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| <b>16:30 - 18:00</b> | <b>Type: Special Symposium</b><br><b>Title: Colorectal cancer: The age makes the difference</b><br>Chair(s): Irit Ben-Aharon, Israel; Demetris Papamichael, Cyprus | <b>Room Barcelona</b> |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|

|               |                                                                                                                                                                             |  |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 16:30 - 16:50 | <b>The patient perspective – Treatment and supportive care: Early-onset patients</b><br><u>Zorana Maravic</u> , DiCE - Digestive Cancers Europe vzw/asbl, Overijse, Belgium |  |
| 16:50 - 17:10 | <b>Older patients</b><br><u>Gabor Liposits</u> , Regional Hospital West Jutland, Herning, Denmark                                                                           |  |
| 17:10 - 17:30 | <b>The disease perspective – The host and environment interplay: Early-onset patients</b><br><u>Irit Ben-Aharon</u> , Rambam Health Care Campus, Haifa, Israel              |  |
| 17:30 - 17:50 | <b>Older patients</b><br><u>Demetris Papamichael</u> , Bank of Cyprus Oncology Centre, Nicosia, Cyprus                                                                      |  |
| 17:50 - 18:00 | <b>Q&amp;A</b>                                                                                                                                                              |  |

|                      |                                                                                                                                            |                    |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| <b>16:30 - 18:00</b> | <b>Type: Educational session</b><br><b>Title: Cancer of the bile ducts</b><br>Chair(s): Angela Lamarca, Spain; Thomas Gruenberger, Austria | <b>Room Madrid</b> |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------|

|               |                                                                                                                                                                         |  |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 16:30 - 16:50 | <b>Surgery of bile duct cancer from resection to liver transplantation</b><br><u>Thomas Gruenberger</u> , Wiener Gesundheitsverbund - Klinik Favoriten, Vienna, Austria |  |
| 16:50 - 17:10 | <b>Treatment of localised gallbladder cancer</b><br><u>Gonzalo Sapisochin</u> , University Health Network - Toronto General Hospital (TGH), Toronto, Canada             |  |
| 17:10 - 17:30 | <b>Use of targeted agents in biliary tract cancer</b><br><u>Do-Youn Oh</u> , Seoul National University Hospital, Seoul, Republic of Korea                               |  |
| 17:30 - 17:50 | <b>New hopes, and new combinations in biliary tract cancer</b><br><u>Angela Lamarca</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain                  |  |
| 17:50 - 18:00 | <b>Q&amp;A</b>                                                                                                                                                          |  |



|                      |                                                                                                                                                                                                                                                                                                                                  |                      |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| <b>16:30 - 18:00</b> | <b>Type: Special session</b><br><b>Title: EORTC special session: Pushing boundaries in GI oncology - Neoadjuvant advances, organ preservation, and novel targets</b><br>Chair(s): Elizabeth Smyth, United Kingdom; Manfred Lutz, Germany                                                                                         | <b>Room Valencia</b> |
| 16:30 - 16:45        | <b>Recent data and future perspectives on neoadjuvant treatment for oesophago-gastric cancers</b><br><u>Hanneke Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands                                                                                                                     |                      |
| 16:45 - 17:00        | <b>Is there a place for organ sparing in gastrointestinal tumours beyond rectal cancer?</b><br><u>Sheraz Markar</u> , University of Oxford, Oxford, United Kingdom                                                                                                                                                               |                      |
| 17:00 - 17:15        | <b>Leveraging the potential of neoadjuvant therapy for localised colon cancer</b><br><u>Gertjan Rasschaert</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium                                                                                                                                  |                      |
| 17:15 - 17:30        | <b>Which TNT regimen to use in locally advanced rectal cancer? Insights from real-world data</b><br><u>Francesco Sclafani</u> , Institute Jules Bordet, Brussels, Belgium                                                                                                                                                        |                      |
| 17:30 - 17:45        | <b>Rare but meaningful: Tumour agnostic therapeutic targets in gastrointestinal cancers</b><br><u>Antonella Cammarota</u> , Humanitas University, Milan, Italy                                                                                                                                                                   |                      |
| 17:45 - 18:00        | <b>Q&amp;A</b>                                                                                                                                                                                                                                                                                                                   |                      |
| <b>18:15 - 19:15</b> | <b>Type: Industry Satellite Symposium</b><br><b>Title: Eisai - Why and when does response matter in 1L HCC management?</b><br>Chair(s): David Pinato, United Kingdom                                                                                                                                                             | <b>Room Madrid</b>   |
| 18:15 - 18:20        | <b>Welcome and introductions</b><br><u>David Pinato</u> , Hammersmith Hospital, London, United Kingdom                                                                                                                                                                                                                           |                      |
| 18:20 - 18:35        | <b>Beyond OS: The importance of other study endpoints in clinical decision making in 1L HCC?</b><br><u>Anna Saborowski</u> <sup>1</sup> , <u>Antonio Guerrero Garcia</u> <sup>2</sup> , <sup>1</sup> MHH - Medizinische Hochschule Hannover, Hannover, Germany, <sup>2</sup> Hospital Universitario Ramon y Cajal, Madrid, Spain |                      |
| 18:35 - 18:50        | <b>Clinical trial insights and RWE on treatment response in patients with HCC</b><br><u>Anna Saborowski</u> <sup>1</sup> , <u>Antonio Guerrero Garcia</u> <sup>2</sup> , <sup>1</sup> MHH - Medizinische Hochschule Hannover, Hannover, Germany, <sup>2</sup> Hospital Universitario Ramon y Cajal, Madrid, Spain                |                      |





18:50 - 19:05 **Real-world insights on treatment duration and PFS, and impact on safety in patients with HCC**

Anna Saborowski<sup>1</sup>, Antonio Guerrero Garcia<sup>2</sup>, <sup>1</sup>MHH - Medizinische Hochschule Hannover, Hannover, Germany, <sup>2</sup>Hospital Universitario Ramon y Cajal, Madrid, Spain

19:05 - 19:15 **Panel discussion and Q&A**

David Pinato<sup>1</sup>, Anna Saborowski<sup>2</sup>, Antonio Guerrero Garcia<sup>3</sup>, <sup>1</sup>Hammersmith Hospital, London, United Kingdom, <sup>2</sup>MHH - Medizinische Hochschule Hannover, Hannover, Germany, <sup>3</sup>Hospital Universitario Ramon y Cajal, Madrid, Spain

**18:15 - 19:15** **Type: Industry Satellite Symposium** **Room Bilbao**  
**Title: Servier - A multidisciplinary approach in cholangiocarcinoma: From clinical evidence to improved patient outcomes**  
Chair(s): Angela Lamarca, Spain; Rachna Shroff, United States of America

18:15 - 18:25 **Introduction: A multidisciplinary approach starts from diagnosis**  
Angela Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

18:25 - 18:35 **Molecular testing in cholangiocarcinoma: Are we there yet?**  
Timothy Kendall, University of Edinburgh, Edinburgh, United Kingdom

18:35 - 18:45 **The surgical management of cholangiocarcinoma**  
Thomas Gruenberger, Wiener Gesundheitsverbund - Klinik Favoriten, Vienna, Austria

18:45 - 18:55 **Precision medicine in advanced cholangiocarcinoma**  
Rachna Shroff, University of Arizona Cancer Center, Tucson, United States of America

18:55 - 19:10 **Clinical case discussion in a multidisciplinary forum**  
Lorenza Rimassa, IRCCS Humanitas Research Hospital, Rozzano, Italy

19:10 - 19:15 **Conclusion**  
Rachna Shroff, University of Arizona Cancer Center, Tucson, United States of America

**18:15 - 19:15** **Type: Industry Satellite Symposium** **Room Malaga**  
**Title: Gilead - Improving patient care in advanced gastroesophageal adenocarcinoma: New directions with immunotherapy**  
Chair(s): Ian Chau, United Kingdom

18:15 - 18:30 **Welcome and introduction: Current immunotherapy landscape in advanced gastroesophageal adenocarcinoma**  
Ian Chau, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom

18:30 - 18:45 **Immunotherapy in advanced gastroesophageal adenocarcinoma: Future directions and patient identification**  
Samuel Klempner, MGH - Massachusetts General Hospital, Boston, United States of America



18:45 - 19:00

**Evolution of biomarker testing: pathologist perspectives**

Mar Iglesias Coma, IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Spain

19:00 - 19:15

**Panel discussion: Multidisciplinary collaboration for improved patient care**

Ian Chau<sup>1</sup>, Samuel Klempner<sup>2</sup>, Mar Iglesias Coma<sup>3</sup>, <sup>1</sup>The Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom, <sup>2</sup>MGH - Massachusetts General Hospital, Boston, United States of America, <sup>3</sup>IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Spain



04.07.2025

**08:30 - 09:45**      **Type: Multidisciplinary Tumour Board**      **Room Madrid**  
**Title: Hepatocellular carcinoma**  
Chair(s): Stephen Chan, Hong Kong SAR, China; Arndt Vogel, Canada

08:30 - 08:40      **Relapse after liver transplantation**  
Arndt Vogel, University of Toronto - Institute of Medical Science, Toronto, Canada

08:40 - 08:55      **Voting and Q&A**  
Arndt Vogel, University of Toronto - Institute of Medical Science, Toronto, Canada

08:55 - 09:10      **Advanced HCC**  
David Pinato, Hammersmith Hospital, London, United Kingdom

09:10 - 09:20      **Voting and Q&A**  
David Pinato, Hammersmith Hospital, London, United Kingdom

09:20 - 09:30      **Intermediate stage**  
Lorenza Rimassa, IRCCS Humanitas Research Hospital, Rozzano, Italy

09:30 - 09:45      **Voting and Q&A**  
Lorenza Rimassa, IRCCS Humanitas Research Hospital, Rozzano, Italy

**08:30 - 09:45**      **Type: Special session**      **Room Valencia**  
**Title: ESMO Gastrointestinal Oncology journal – Selected manuscripts**  
Chair(s): Irit Ben-Aharon, Israel; Florian Lordick, Germany

08:30 - 08:45      **Evolving challenges for early onset gastrointestinal cancer**  
Cathy Eng, Vanderbilt Ingram Cancer Center, Nashville, United States of America

08:45 - 09:00      **Clinical impact of circulating tumour DNA to track minimal residual disease in colorectal cancer patients: Hopes and limitations**  
Julien Taieb, Hopital European George Pompidou, Paris, France

09:00 - 09:15      **Oligometastatic disease in esophagogastric cancer: An update of recommendations on definition, diagnosis, and treatment**  
Hanneke Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

09:15 - 09:30      **Exploring the pathway: Clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies**  
Christoph Benedikt Westphalen, LMU Klinikum der Universität München, Munich, Germany

09:30 - 09:45      **Q&A**



|                      |                                                                                                                                                                                                     |                       |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| <b>08:45 - 09:45</b> | <b>Type: Controversy session</b><br><b>Title: Organ preservation in MSI colon cancer</b><br>Chair(s): Andres Cervantes, Spain                                                                       | <b>Room Barcelona</b> |
| 08:45 - 08:55        | <b>Introduction</b><br><u>Andres Cervantes</u> , Hospital Clinico Universitario de Valencia, Valencia, Spain                                                                                        |                       |
| 08:55 - 09:15        | <b>Pro</b><br><u>Myriam Chalabi</u> , Netherlands Cancer Institute, Amsterdam, Netherlands                                                                                                          |                       |
| 09:15 - 09:35        | <b>Con</b><br><u>Andrea Cercek</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, United States of America                                                                    |                       |
| 09:35 - 09:45        | <b>Q&amp;A and discussion</b><br><u>Andres Cervantes</u> , Hospital Clinico Universitario de Valencia, Valencia, Spain                                                                              |                       |
| <b>10:00 - 10:30</b> | <b>Type: Keynote session</b><br><b>Title: Blood tests for colorectal cancer screening and more wide cancer screening</b>                                                                            | <b>Room Barcelona</b> |
| 10:00 - 10:05        | <b>Introduction to the Keynote Speaker</b>                                                                                                                                                          |                       |
| 10:05 - 10:30        | <b>Blood tests for colorectal cancer screening and more wide cancer screening</b><br><u>Frank Sinicrope</u> , Mayo Clinic - Rochester, Rochester, United States of America                          |                       |
| <b>10:30 - 11:00</b> | <b>Type: Coffee break</b><br><b>Title: Coffee break</b>                                                                                                                                             | <b>Foyer</b>          |
| <b>11:00 - 12:30</b> | <b>Type: Educational session</b><br><b>Title: Individualised treatment of localised rectal cancer</b><br>Chair(s): Regina Beets-Tan, Netherlands                                                    | <b>Room Barcelona</b> |
| 11:00 - 11:20        | <b>How to stratify risk for rectal cancer patients using imaging</b><br><u>Regina Beets-Tan</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands    |                       |
| 11:20 - 11:40        | <b>Strategies in low-intermediate risk of rectal cancer: NOM &amp; surgical strategies</b><br><u>André D'hoore</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium |                       |
| 11:40 - 12:00        | <b>Strategy in high risk of rectal cancer</b><br><u>Christos Karapetis</u> , Flinders Centre for Innovation in Cancer, Bedford Park, Australia                                                      |                       |



|                      |                                                                                                                                                                                                                                                                                                                                     |                    |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| 12:00 - 12:20        | <b>Quality of life and rectal cancer</b><br><u>David Sebag-Montefiore</u> , St. James's University Hospital, Leeds, United Kingdom                                                                                                                                                                                                  |                    |
| 12:20 - 12:30        | <b>Q&amp;A</b>                                                                                                                                                                                                                                                                                                                      |                    |
| <b>11:00 - 12:30</b> | <b>Type: Educational session</b><br><b>Title: Gastro-oesophageal cancer</b><br>Chair(s): Yelena Janjigian, United States of America                                                                                                                                                                                                 | <b>Room Madrid</b> |
| 11:00 - 11:20        | <b>Treatment of non-metastatic squamous oesophageal cancer</b><br><u>Guillaume Piessen</u> , C.H.U. Claude Huriez, Lille, France                                                                                                                                                                                                    |                    |
| 11:20 - 11:40        | <b>Treatment of non-metastatic gastro-oesophageal adenocarcinoma</b><br><u>Florian Lordick</u> , Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, Germany                                                                                                                                                |                    |
| 11:40 - 12:00        | <b>Immunotherapy in gastro-oesophageal cancer</b><br><u>Yelena Janjigian</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America                                                                                                                                                                   |                    |
| 12:00 - 12:20        | <b>New targeted therapies in gastro-oesophageal cancer</b><br><u>Elizabeth Smyth</u> , Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, United Kingdom                                                                                                                                                |                    |
| 12:20 - 12:30        | <b>Q&amp;A</b>                                                                                                                                                                                                                                                                                                                      |                    |
| <b>12:45 - 13:45</b> | <b>Type: Industry Satellite Symposium</b><br><b>Title: Jazz Pharmaceuticals - Innovations in biliary tract cancers: Guiding the path to better outcomes</b><br>Chair(s): Andrea Casadei Gardini, Italy                                                                                                                              | <b>Room Madrid</b> |
| 12:45 - 12:52        | <b>Defining the unmet needs in BTC: Improving access to targeted therapies</b><br><u>Andrea Casadei Gardini</u> , UniSR - Università Vita e Salute San Raffaele Milano, Milan, Italy                                                                                                                                                |                    |
| 12:52 - 13:12        | <b>Tailoring treatment strategies: The importance of early and comprehensive molecular testing</b><br><u>Albrecht Stenzinger</u> <sup>1</sup> , <u>Julien Edeline</u> <sup>2</sup> , <sup>1</sup> University Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany, <sup>2</sup> Centre Eugene - Marquis, Rennes, France |                    |
| 13:12 - 13:27        | <b>Advancing treatment: New targeted therapies for advanced HER2+ BTC</b><br><u>Angela Lamarca</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain                                                                                                                                                                   |                    |

|               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 13:27 - 13:42 | <p><b>Panel discussion and audience Q&amp;A</b></p> <p><u>Andrea Casadei Gardini</u><sup>1</sup>, <u>Angela Lamarca</u><sup>2</sup>, <u>Julien Edeline</u><sup>3</sup>, <u>Albrecht Stenzinger</u><sup>4</sup>, <sup>1</sup>UniSR - Università Vita e Salute San Raffaele Milano, Milan, Italy, <sup>2</sup>Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain, <sup>3</sup>Centre Eugene - Marquis, Rennes, France, <sup>4</sup>University Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany</p> |
| 13:42 - 13:45 | <p><b>Summary and close</b></p> <p><u>Andrea Casadei Gardini</u>, UniSR - Università Vita e Salute San Raffaele Milano, Milan, Italy</p>                                                                                                                                                                                                                                                                                                                                                                                   |
| 12:45 - 13:45 | <p><b>Type: Industry Satellite Symposium</b> <b>Room Bilbao</b></p> <p><b>Title: AstraZeneca - Evolving treatment landscape for resectable GC / GEJC</b></p> <p>Chair(s): Yelena Janjigian, United States of America</p>                                                                                                                                                                                                                                                                                                   |
| 12:45 - 12:50 | <p><b>Welcome and introductions</b></p> <p><u>Yelena Janjigian</u>, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America</p>                                                                                                                                                                                                                                                                                                                                                                 |
| 12:50 - 13:05 | <p><b>Plenary: Optimising treatment strategies and addressing unmet needs in resectable GC / GEJC</b></p> <p><u>Kohei Shitara</u>, National Cancer Center Hospital East, Kashiwa, Japan</p>                                                                                                                                                                                                                                                                                                                                |
| 13:05 - 13:20 | <p><b>Plenary: Tolerability and management of perioperative FLOT</b></p> <p><u>Sylvie Lorenzen</u>, Klinikum Rechts der Isar - Technische Universität München, Munich, Germany</p>                                                                                                                                                                                                                                                                                                                                         |
| 13:20 - 13:45 | <p><b>Panel discussion and Q&amp;A: Considerations for the treatment of resectable GC / GEJC</b></p> <p><u>Yelena Janjigian</u><sup>1</sup>, <u>Sylvie Lorenzen</u><sup>2</sup>, <u>Kohei Shitara</u><sup>3</sup>, <sup>1</sup>MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America, <sup>2</sup>Klinikum Rechts der Isar - Technische Universität München, Munich, Germany, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, Japan</p>                                            |
| 12:45 - 13:45 | <p><b>Type: Industry Satellite Symposium</b> <b>Room Malaga</b></p> <p><b>Title: Servier - Metastatic pancreatic cancer: Towards a change in patient care?</b></p> <p>Chair(s): Thomas Seufferlein, Germany; Gerald Prager, Austria</p>                                                                                                                                                                                                                                                                                    |
| 12:45 - 12:50 | <p><b>Introduction</b></p> <p><u>Thomas Seufferlein</u>, University of Ulm, Ulm, Germany</p>                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 12:50 - 13:10 | <p><b>Controversies on the 1L metastatic pancreatic cancer</b></p> <p><u>Thomas Seufferlein</u><sup>1</sup>, <u>Gerald Prager</u><sup>2</sup>, <u>Cindy Neuzillet</u><sup>3</sup>, <sup>1</sup>University of Ulm, Ulm, Germany, <sup>2</sup>Universitätskliniken der MedUni Wien - AKH Wien, Vienna, Austria, <sup>3</sup>Institut Curie, Paris, France</p>                                                                                                                                                                |
| 13:10 - 13:25 | <p><b>Reflecting on a patient case: Key takeaways</b></p> <p><u>Jörg Trojan</u>, Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, Germany</p>                                                                                                                                                                                                                                                                                                                                       |



13:25 - 13:40 **First insights from everyday clinical practice: A new standard in 1L?**  
Holger Rumpold, Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria

13:40 - 13:45 **Conclusion**  
Gerald Prager, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, Austria

**12:45 - 13:45** **Type: Industry Satellite Symposium** **Room Valencia**  
**Title: Medscape Global Oncology - BRAF-mutated metastatic colorectal cancer: Real-world insights, personalized impact**  
Chair(s): Julien Taieb, France

12:45 - 12:50 **Welcome and introduction**  
Julien Taieb, Hopital European George Pompidou, Paris, France

12:50 - 13:05 **mCRC in motion: Rapid-fire updates on science and practice**

13:05 - 13:15 **Molecular testing in mCRC: A roadmap to personalized care**  
Mar Iglesias Coma, IMIM - Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Spain

13:15 - 13:40 **Case by case: Unravelling complex treatment decisions**

13:40 - 13:45 **Q&A, concluding remarks and EBAC evaluation**  
Julien Taieb, Hopital European George Pompidou, Paris, France

**12:45 - 13:30** **Type: Young Oncologists session** **Foyer**  
**Title: YO session: Vesalius talk**  
Chair(s): Rille Pihlak, United Kingdom; Deniz Can Guven, Türkiye

12:45 - 13:30 **What skills young oncologist need to build a great career in GI oncology**  
Rachel Riechelmann<sup>1</sup>, Arndt Vogel<sup>2</sup>, Julien Taieb<sup>3</sup>, <sup>1</sup>A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, Brazil, <sup>2</sup>University of Toronto - Institute of Medical Science, Toronto, Canada, <sup>3</sup>Hopital European George Pompidou, Paris, France

**14:00 - 15:30** **Type: Special Symposium** **Room Barcelona**  
**Title: New immunotherapy concepts in GI cancers**  
Chair(s): Kohei Shitara, Japan

14:00 - 14:20 **CAR and engineered TCRs**  
Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan

14:20 - 14:40 **MRNA and oncopeptide vaccines**  
Vinod Balachandran, MSKCC - Memorial Sloan Kettering Westchester, West Harrison, United States of America



- 14:40 - 15:00      **Modulation of 'cold' immune milieu**  
Michael Overman, The University of Texas MD Anderson Cancer Center - Main Building,  
Houston, United States of America
- 15:00 - 15:20      **BiTEs & BiKEs, TRiTEs and TRiKEs**  
Elisa Fontana, Sarah Cannon Research Institute SCRI UK, London, United Kingdom
- 15:20 - 15:30      **Q&A**

|                      |                                                                   |                    |
|----------------------|-------------------------------------------------------------------|--------------------|
| <b>14:00 - 15:30</b> | <b>Type: Educational session</b><br><b>Title: Rare GI cancers</b> | <b>Room Madrid</b> |
|----------------------|-------------------------------------------------------------------|--------------------|

- 14:00 - 14:20      **State-of-the-art management and emerging breakthroughs in anal cancer**  
Sheela Rao, The Royal Marsden Hospital - Chelsea, London, United Kingdom
- 14:20 - 14:40      **Optimising therapy for patients with localised GIST**  
Jean-Yves Blay, Centre Léon Bérard, Lyon, France
- 14:40 - 15:00      **Rare peritoneal diseases**  
Jorge Barriuso, Hospital Universitario 12 de Octubre, Madrid, Spain
- 15:00 - 15:20      **Fibrolamellar hepatocellular carcinoma**  
Bruno Sangro, Clinica Universidad de Navarra, Pamplona, Spain
- 15:20 - 15:30      **Q&A**

|                      |                                                                                              |              |
|----------------------|----------------------------------------------------------------------------------------------|--------------|
| <b>15:30 - 16:30</b> | <b>Type: Poster Display session</b><br><b>Title: Poster display session and coffee break</b> | <b>Foyer</b> |
|----------------------|----------------------------------------------------------------------------------------------|--------------|

- 15:30 - 15:30      **8P - Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases**  
Benjamin Schlechter, Dana Farber Cancer Institute, Boston, United States of America
- 15:30 - 15:30      **9P - Phase 1 Dose-Escalation Study of GCC19CART: A Novel CAR T-Cell Therapy for Metastatic Colorectal Cancer in the United States**  
Benjamin Schlechter, Dana-Farber Cancer Institute, Boston, United States of America
- 15:30 - 15:30      **10P - Phase 1 Study of Magrolimab (ONO-7913) and Nivolumab (ONO-4538, NIV) in Combination with FOLFOX and Bevacizumab (Bev) or Cetuximab (Cet) as First-Line Treatment in Patients with Unresectable Advanced or Recurrent Colorectal Cancer (CRC)**  
Kensei Yamaguchi, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan





- 15:30 - 15:30      **11P - NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I Study**  
Haojie Zhou, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
- 15:30 - 15:30      **12P - ORGANOTREAT-01: a pioneer Phase I/II Multicenter Trial of Organoid-Driven Precision Medicine for Refractory Colorectal Cancer**  
Fanny Jaulin, Gustave Roussy - Cancer Campus, Villejuif, France
- 15:30 - 15:30      **13P - Integrating tissue (TBx) and liquid biopsy (LBx) comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer (mCRC): findings from the CAPRI-2 GOIM study**  
Eleonora Cioli, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
- 15:30 - 15:30      **14P - Comprehensive genomic profiling to guide personalized targeted and immunotherapy in gastrointestinal tumors: subgroup analysis of the ROME trial**  
Chiara Cremolini, University of Pisa, Pisa, Italy
- 15:30 - 15:30      **15P - Clinical relevance of tumor fraction assessment from circulating tumor DNA and RNF43 mutations as predictors of anti-BRAF/EGFR outcomes in metastatic colorectal cancer**  
Rodrigo Toledo, VHIO - Vall d'Hebron Institute of Oncology, Barcelona, Spain
- 15:30 - 15:30      **16P - Early ctDNA decrease predicts survival in MSI Metastatic Colorectal Cancer treated with immunotherapy**  
Julien Taieb, Hopital European George Pompidou, Paris, France
- 15:30 - 15:30      **17P - Clinical Utility of Liquid Biopsy in Patients with Metastatic Non-Resectable CRC**  
Mahmoud Yousef, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- 15:30 - 15:30      **18P - Combined analysis of Plasmatic Mutant Allele Fraction (pMAF) and RECISTv1.1 in MSI metastatic ColoRectal Cancer (mCRC) treated with immune-checkpoint inhibitors (ICI).**  
Francisco Javier Ros Montana, Vall d'Hebron University Hospital, Barcelona, Spain
- 15:30 - 15:30      **19P - Circulating tumor DNA (ctDNA) dynamics predict clinical recurrence in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment**  
Vittorio Studiale, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
- 15:30 - 15:30      **20P - Plasmatic biomarkers of BRAF inhibitor combination therapy for BRAF-mutated metastatic colorectal cancer: Insights from the BEETS trial (JACCRO CC-18)**  
Chiaki Inagaki, Kindai University - Faculty of Medicine, Osaka, Japan
- 15:30 - 15:30      **21P - Real-world genomic profiles in patients with HER2-positive metastatic colorectal cancer**  
Yuki Matsubara, National Cancer Center Hospital East, Kashiwa, Japan



- 15:30 - 15:30      **22P - Clinical and Genomics Characterization of PIK3CA-Mutant (mPIK3CA) Metastatic Colorectal Cancer (mCRC) at a Brazilian Cancer Center: A Real-World Data Analysis**  
Leonardo Santana, A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, Brazil
- 15:30 - 15:30      **23P - Prognostic Impact of Secondary Actionable Alterations in dMMR/MSI-H Digestive Tumors**  
Nieves Martinez Lago, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela, Galician Healthcare Service (SERGAS), Santiago de Compostela, Spain
- 15:30 - 15:30      **24P - Precision Medicine in Colorectal Cancer: Personalizing Treatment for Improved Outcomes?**  
Charbel Soueidy, Institut Gustave Roussy, Villejuif, France
- 15:30 - 15:30      **25P - Reflex Molecular Biomarker Testing in Colorectal Cancer: Pathway Insights from the South-East England Network**  
Wing Kin Liu, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
- 15:30 - 15:30      **26P - Transcriptomic and Prognostic Signatures Differentiate Peritoneal from Liver Metastases in Colorectal Cancer**  
Noor Al-Bzour, JUST - Jordan University of Science and Technology, Irbid, Jordan
- 15:30 - 15:30      **27P - Study of tumor mutational variation measured by NGS in patients with BRAF-mutated metastatic colorectal cancer undergoing surgery after prior systemic treatment**  
Javier Soto Alsar, Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, Spain
- 15:30 - 15:30      **28P - Comprehensive genomic profiling (CGP) of colorectal cancer ovarian metastases.**  
Laura Chiofalo, Università Cattolica del Sacro Cuore, Rome, Italy
- 15:30 - 15:30      **29P - Mismatch repair a biomarker of prognosis and overall survival of Latin American with colorectal metastatic patients**  
Luisa Rivero Zambrano, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico
- 15:30 - 15:30      **30P - T cell – cancer cell interaction in prediction of response to EGFR-, VEGF-inhibitors or no biologics in first line treatment of metastatic colorectal cancer (mCRC) patients**  
Pia Osterlund, Tampere University Hospital (Tays), Tampere, Finland
- 15:30 - 15:30      **31P - Derived neutrophil-to-lymphocyte ratio (dNLR) as a prognostic marker in metastatic colorectal cancer (mCRC) – RAXO substudy**  
Minna Meklin, North Karelia Central Hospital, Siun sote, Joensuu, Finland
- 15:30 - 15:30      **32P - A novel imaging biomarker, quantitative vessel tortuosity, captures the antiangiogenic effect of fruquintinib in metastatic colorectal cancer**  
Sara Lonardi, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy



- 15:30 - 15:30      **33P - Unveiling the patterns: clinical and molecular traits of brain metastases (BM) in colorectal cancer (CRC)**  
Mario Balsa Pena, ICO - Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
- 15:30 - 15:30      **34P - Relevance of ABCG2 and SRPK1 genetic variants in irinotecan-induced severe toxicity**  
Iván Martín Da Silva, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 15:30 - 15:30      **35P - Clinical outcomes of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab by metastasis status in RAS/BRAF wild-type and left-sided metastatic colorectal cancer: the DEEPER trial (JACCRO CC-13)**  
Yu Sunakawa, St. Marianna University School of Medicine, Kawasaki, Japan
- 15:30 - 15:30      **36P - BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6**  
Takayuki Yoshino, National Cancer Center Hospital East, Kashiwa, Japan
- 15:30 - 15:30      **37P - Efficacy and safety of fruquintinib vs placebo by metastatic site in metastatic colorectal cancer: A FRESCO-2 subgroup analysis**  
Rocio Garcia-Carbonero, Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, Spain
- 15:30 - 15:30      **38P - Real-world use of encorafenib + cetuximab (EC) in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC): a pooled analysis of European observational studies**  
Chiara Cremolini, University of Pisa, Pisa, Italy
- 15:30 - 15:30      **39P - AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual Patient Data (IPD) pooled analysis of randomized clinical trials (RCTs)**  
Alessandra Raimondi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- 15:30 - 15:30      **40P - Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study – BERING CRC**  
Sebastian Stintzing, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 15:30 - 15:30      **41P - Switch from cetuximab (CET) to panitumumab (PANI) during encorafenib (ENCO)-based therapy in BRAF V600E mutated metastatic colorectal cancer (mCRC): an international multicenter analysis from the AGEO group.**  
Annalice Gandini, HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, France
- 15:30 - 15:30      **42P - Real-world outcomes of anti-EGFR rechallenge in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC)**  
Pau Mascaró Baselga, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain



- 15:30 - 15:30      **43P - A Canadian Real-World Evidence Study of Panitumumab with Encorafenib in BRAF V600E Mutated Metastatic Colorectal Cancer (mCRC)**  
Winson Cheung, University of Calgary, Calgary, Canada
- 15:30 - 15:30      **44P - Rechallenge with anti-HER2 regimens in metastatic colorectal cancer: the retrospective RHEA study**  
Andrea Sartore Bianchi, Università degli Studi di Milano, Milan, Italy
- 15:30 - 15:30      **45P - Real life comparison of toxicity from cetuximab and panitumumab in the first line treatment of metastatic colorectal cancer**  
Calum Polwart, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom
- 15:30 - 15:30      **46P - Real World First-line Treatment Outcomes of Patients with KRAS G12C- or non- G12C KRAS Mutated Metastatic Colorectal Cancer in the US**  
Cathy Eng, Vanderbilt Ingram Cancer Center, Nashville, United States of America
- 15:30 - 15:30      **47P - Sequence analysis of three different treatment alternatives for patients with left-side RAS wild type metastatic colorectal cancer in Spain**  
Beatriz García-Paredes, Clínico San Carlos University Hospital, Madrid, Spain
- 15:30 - 15:30      **48P - Impact of the KRAS mutation subtype on treatment response in metastatic colorectal cancer**  
Nohad Masri, Institut Gustave Roussy, Villejuif, France
- 15:30 - 15:30      **49P - A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer**  
Ka Yan Lai, Queen Elizabeth Hospital, Kowloon, Hong Kong SAR, China
- 15:30 - 15:30      **50P - First-line treatment in MSI-H/dMMR metastatic colorectal cancer across Europe, Canada and the United States: A real-world survey of patients and clinicians**  
Jenny Seligmann, The University of Leeds, Leeds, United Kingdom
- 15:30 - 15:30      **51P - Outcomes and management of primary tumors in metastatic MSI/dMMR colorectal cancer patients treated with immune checkpoint inhibitors : a cohort study.**  
Léo Mas, Institut Universitaire de Cancérologie AP-HP Sorbonne Université - Hôpital Saint-Antoine, Paris, France
- 15:30 - 15:30      **52P - Pembrolizumab real-world data, including inflammatory indices in dMMR/MSI-H mCRC from a tertiary cancer centre**  
Eleftherios Christodoulis, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 15:30 - 15:30      **53P - Microsatellite-instability-high/ mismatch-repair-deficient (MSI-H/dMMR) and BRAFV600E mutant (BRAFM) advanced colorectal cancers (CRC) treated with immune checkpoint inhibitors (ICI): Real-world data from the Royal Marsden Hospital**  
Ha Mo Linh Le, The Royal Marsden Hospital - Chelsea, London, United Kingdom



- 15:30 - 15:30      **54P - Oligoprogression under immune checkpoint inhibitors (ICI) for metastatic colorectal cancer with microsatellite instability: A Distinct Entity Requiring Tailored Management**  
Clément Grosnon, Institut Universitaire de Cancérologie AP-HP Sorbonne Université - Hôpital Saint-Antoine, Paris, France
- 15:30 - 15:30      **55P - Combining systemic treatments and multiple surgical resections in oligometastatic colorectal cancer patients: a referral center experience.**  
Giovanni Trovato, Policlinico Universitario Agostino Gemelli, Rome, Italy
- 15:30 - 15:30      **56eP - Liver Transplantation or Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases – A Meta-Analysis of Reconstructed Single-arm Survival Data**  
Owen Jones, University Health Network - Toronto General Hospital (TGH), Toronto, Canada
- 15:30 - 15:30      **57P - Hepatic Arterial Infusion with Mitomycin C in patients with Colorectal Liver Metastases**  
Julie Vandewinckele, Institut Gustave Roussy, Villejuif, France
- 15:30 - 15:30      **58P - Surgery versus ablation for colorectal liver metastases: a tertiary referral hospital experience**  
Filipa Verdasca, Unidade Local de Saúde de São José, Lisbon, Portugal
- 15:30 - 15:30      **59P - Development and validation of a simple scoring system to identify patients with poor outcomes from resection of colorectal liver metastases (CRLM) despite technical resectability**  
Huili James Chong, Northampton General Hospital (NGH), University Hospitals of Northamptonshire, Northampton, United Kingdom
- 15:30 - 15:30      **60P - No liver metastases vs liver metastases in metastatic colorectal cancer (mCRC)**  
Emerik Osterlund, Turku University Hospital (Tyks), Turku, Finland
- 15:30 - 15:30      **61P - Correlation between Survival Outcomes and Duration of Sequential Treatment with Regorafenib and Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: Results from the Multicenter Retrospective ReTrITA Study**  
Carlo Signorelli, Medical Oncology Unit, S.Rosa Hospital, ASL Viterbo, Viterbo, Italy
- 15:30 - 15:30      **62P - Trifluridine/tipiracil plus bevacizumab (TTB) versus regorafenib (R) in refractory advanced colorectal cancer patients: a Real-World Evidence efficacy study.**  
Jesus Rodriguez Pascual, Instituto Oncologico Vithas, Madrid, Spain
- 15:30 - 15:30      **63P - Pooled safety analysis of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC) using individual patient data (IPD) from five clinical trials**  
Kentarō Yamazaki, Shizuoka Cancer Center, Shizuoka, Japan

- 15:30 - 15:30      **64P - PROMETCO: real-world characteristics and safety outcomes of patients with metastatic colorectal cancer (mCRC) after two disease progressions, including patients with ECOG-PS >2**  
Rocio Garcia-Carbonero, University Hospital 12 De Octubre, Madrid, Spain
- 15:30 - 15:30      **65P - BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal Cancer**  
Qun Zhang, Nanjing Drum Tower Hospital, Nanjing, China
- 15:30 - 15:30      **66P - Real World Data from Fruquintinib in Later Line Metastatic Colorectal Cancer**  
Filipa Verdasca, Unidade Local de Saúde de São José, Lisbon, Portugal
- 15:30 - 15:30      **67P - Physicians' preferences for later-line treatment of metastatic colorectal cancer in Germany and the UK**  
Ashley Geiger, Takeda Development Center Americas (TDCA), Inc., Cambridge, United States of America
- 15:30 - 15:30      **68P - Patients' treatment experiences and involvement in treatment decision-making in metastatic colorectal cancer: results of a patient survey in Europe and Canada**  
Mark Saunders, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 15:30 - 15:30      **69P - Prognostic impact of weight loss on overall survival in metastatic colorectal cancer: a call for integrating nutritional interventions into oncological care**  
Adriana Alcaraz, Vall d'Hebron University Hospital, Barcelona, Spain
- 15:30 - 15:30      **70P - Prognostic Implications of Bone Metastasis in Early-Onset Colorectal Cancer**  
Deepak Vadehra, Roswell Park Comprehensive Cancer Center, Buffalo, United States of America
- 15:30 - 15:30      **71P - Management of Adolescents and Young Adults (AYA) metastatic Colorectal Cancer (mCRC) patients (pts): a single institution analysis.**  
Alexia Spring, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 15:30 - 15:30      **72P - Early-Onset Colorectal Cancer Patients Exhibits a Distinct Molecular Fingerprint: Insights from a Study of 1209 Patients Using NGS**  
Andrea Pretta, Medical Oncology Unit, University Hospital and University of Cagliari, Monserrato, Italy
- 15:30 - 15:30      **73P - Proteome analysis of patients with colorectal cancer in Ireland**  
Mary O'Reilly, St Vincent's University Hospital, Dublin, Ireland
- 15:30 - 15:30      **74P - Deciphering the Proteomic Landscape of Pregnancy-Associated Colorectal Cancer**  
Irit Ben-Aharon, Rambam Health Care Campus, Haifa, Israel
- 15:30 - 15:30      **75P - Clinical and Molecular characteristics of young onset Colorectal Cancers**  
Elie Akoury, Gustave Roussy, Villejuif, France



- 15:30 - 15:30      **76P - Comparative Molecular and Clinical Landscape of Early- vs Late-Onset Advanced Colorectal Cancer**  
Diana Rosero Rodriguez, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
- 15:30 - 15:30      **77P - Survival Outcomes and Molecular Characteristics of Early-Onset Colorectal Cancer Patients (EOCRC): a Multiracial Cohort**  
Evelyn Wong, National Cancer Centre Singapore, Singapore, Singapore
- 15:30 - 15:30      **78P - Comparative analysis of molecular alterations in colorectal cancer patients under 50 and over 50: insights from next-generation sequencing**  
Mario Balsa Pena, ICO - Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain
- 15:30 - 15:30      **79P - miR-195 and miR-549a as potential biomarkers for early-onset colorectal cancer**  
Jossimar Coronel, INCAN - Instituto Nacional de Cancerologia, Mexico City, Mexico
- 15:30 - 15:30      **80P - Tumor Immune Microenvironment in Young, Multi-Ethnic Colorectal Cancer Patients**  
Mohamed Salem, Levine Cancer Institute - Morehead, Charlotte, United States of America
- 15:30 - 15:30      **81P - Tumour microbiome and immune dysregulation in early-onset colorectal cancer**  
Rachel Purcell, University of Otago, Christchurch, New Zealand
- 15:30 - 15:30      **82P - Intratumoral presence of the genotoxic gut bacteria pks+ E. coli in very early onset colorectal cancer**  
Gianluca Mauri, Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 15:30 - 15:30      **83P - Colorectal cancer in the young and old patients: a 30-year analysis at the Modena Cancer Center**  
Bianca Medici, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, Italy
- 15:30 - 15:30      **84P - Towards a tailored care program: Exploring the characteristics of EOCRC patients at a comprehensive cancer center in Germany**  
Katja Kaunath, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany
- 15:30 - 15:30      **85P - Early Onset Colorectal Cancer: Linking clinical outcomes to socio-economic challenges across three tertiary cancer centres.**  
Angelos Angelakas, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 15:30 - 15:30      **86P - Prevalence of PIK3CA and PTEN alterations from upfront genomic testing of newly diagnosed colorectal cancer (CRC): a population-based series.**  
Laura Kerrin, Belfast City Hospital, Belfast, United Kingdom



- 15:30 - 15:30      **87P - Characterization, though multidimensional analyses, of different subsets of immune cells and soluble molecules in the peripheral blood of colorectal cancer patients to identify candidate biomarkers for patients' clinical outcome**  
Kakil Rasul, Hamad Medical Corporation (HMC) - National Center for Cancer Care and Research (Al Amal Hospital), Doha, Qatar
- 15:30 - 15:30      **88P - Dissecting the Transverse Colon by Embryologic Origin: A Monocentric Retrospective Study of Midgut- and Hindgut-Derived Tumors**  
Beatrice Riccò, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, Italy
- 15:30 - 15:30      **89P - Development of methylation-based biomarkers to predict metastases, treatment effect, and microsatellite status in colorectal cancer**  
John Paul Shen, The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America
- 15:30 - 15:30      **90P - Clinicopathological Distinctions Between MSS and MSI-H Colorectal Tumors in Patients with Lynch Syndrome**  
Oladimeji Lanade, Atrium Health Levine Cancer, Charlotte, United States of America
- 15:30 - 15:30      **91P - Enumeration and Immunophenotype of Circulating Tumor Cells in Colorectal Cancer Patients**  
Ana Paz, White Clinic private practice, Algés, Portugal
- 15:30 - 15:30      **92P - Real-World Evidence of a Tissue-Free ctDNA-Based Minimal Residual Disease (MRD) Testing in Colorectal Cancer (CRC): Insights from an Indian Cohort**  
Viraj Lavingia, Shalby Hospitals, Ahmedabad, India
- 15:30 - 15:30      **93P - Clinical validation of a methylation-based, tissue-free colorectal cancer test for the detection of molecular residual disease by circulating tumor DNA**  
Yoshiaki Nakamura, National Cancer Center Hospital East, Kashiwa, Japan
- 15:30 - 15:30      **94P - Integrating Circulating Biomarkers, TLRs/VDRs polymorphisms and Microbial Translocation for Prognosis in Stage III Colorectal Cancer.**  
Asimina Koulouridi, GOC - German Oncology Center, Λεμεσός, Cyprus
- 15:30 - 15:30      **95P - Adding quantitation to a tumor-informed molecular residual disease (MRD) assay to measure circulating tumor DNA as a marker of recurrence risk in patients with stage III colorectal cancer (CRC)**  
Robert Schoen, University of Pittsburgh, Pittsburgh, United States of America
- 15:30 - 15:30      **96P - Integrative risk stratification in stage II-III colorectal cancer: associations between molecular alterations, microbial translocation, and TLR polymorphisms**  
Andreas Koulouris, Gastrointestinal Cancer Study Group, Heraklion, Greece



- 15:30 - 15:30      **97P - Immune Profiling Enhances Stratification in Stage II Colon Cancer (CC): A Novel Approach Integrating Consensus Molecular Subtype (CMS) Classification and Immune Cell (IC) Infiltration**  
Cristina Santos Vivas, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, Spain
- 15:30 - 15:30      **98P - A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth**  
Yunshi Zhong, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
- 15:30 - 15:30      **99P - A Multi-Marker Panel for CMS-Based Molecular Classification of Colorectal Cancer in a Latin American Cohort**  
Aracelly Quiroz, University of Concepcion, Concepcion, Chile
- 15:30 - 15:30      **100P - Vascular Endothelial Growth Factor in Colorectal Cancer Progression and 5, 10 and 15 year Survival**  
Deborah Wilson, University Hospital Of North Tees - North Tees and Hartlepool NHS Foundation Trust, Stockton on Tees, United Kingdom
- 15:30 - 15:30      **101P - Cost-Effectiveness of Liquid Biopsy in Stage II Colon Cancer: A Real-World Analysis**  
Valentino Martelli, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 15:30 - 15:30      **102P - Direct cost of healthcare analysis of Signatera ctDNA testing in the adjuvant setting for a hypothetical cohort of stage II and stage III colorectal cancer (CRC) patients: a UK private payer perspective.**  
Christos Mikropoulos, Royal Surrey Hospital & BUPA UK Insurance, Guildford, United Kingdom
- 15:30 - 15:30      **103P - Age Cut-off for Oxaliplatin Efficacy in Stage II/III Colorectal Cancer**  
Sanghee Kang, Korea University College of Medicine, Seoul, Republic of Korea
- 15:30 - 15:30      **104P - Deep Learning-Based Automated Prognostic Stratification Through Analysis of Invasive Margin T-Cell Infiltrates in Localized Colon Cancer**  
Julie Lecuelle, Centre Georges-François Leclerc (Dijon), Dijon, France
- 15:30 - 15:30      **105P - Artificial Intelligence (ChatGPT-4o) in Adjuvant Treatment Decision-Making for Stage II Colon Cancer: A Comparative Analysis with Clinician Recommendations and NCCN/ESMO Guidelines**  
Hasan Yildirim, Hacettepe University Oncology Hospital, Ankara, Türkiye
- 15:30 - 15:30      **106P - Neoadjuvant immunotherapy with prolgolimab in locally advanced dMMR/MSI colorectal cancer: final pathological response analysis and 12-months disease-free survival**  
Olesya Kuznetsova, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation



- 15:30 - 15:30      **107P - Efficacy of pembrolizumab and feasibility of organ preservation in non-metastatic, unresectable dMMR CRC**  
Lauren Van Den Dungen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- 15:30 - 15:30      **108P - Short course immunotherapy as curative-intended treatment in stage I-III mismatch repair deficient rectal cancer**  
Line Tarpgaard, OUH - Odense University Hospital, Fredericia, Denmark
- 15:30 - 15:30      **109P - Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer: The West of Scotland Experience**  
Neal C Ramchander, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
- 15:30 - 15:30      **110P - Phase II trial of low dose neoadjuvant immunotherapy in locally advanced MSI/dMMR colorectal cancer: first safety and efficacy outcomes.**  
Albina Zagidullina, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
- 15:30 - 15:30      **111P - Neoadjuvant high-dose vitamin C (HDVC) combined with ipilimumab and nivolumab in proficient mismatch repair (pMMR) colon cancer (CC): first safety analysis of ALFEO pilot study**  
Alessio Amatu, Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 15:30 - 15:30      **112P - Defining Who Benefits: Adjuvant Treatment Patterns and Survival Outcomes in Stage II Colon Cancer — A Multicenter Real-World Analysis**  
Tiago Pina-Cabral, Unidade Local de Saúde Lisboa Ocidental, Lisbon, Portugal
- 15:30 - 15:30      **113P - Safety of adjuvant S-1 after capecitabine-induced toxicity in patients with colon cancer: a population-based real-world study.**  
Avin Ghedri, UMC-University Medical Center Utrecht, Utrecht, Netherlands
- 15:30 - 15:30      **114P - Radiologist Concordance and Pathology Correlation in Non Metastatic Colon Cancer (NMCC) Staging**  
Giovanni Randon, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
- 15:30 - 15:30      **115P - Changes in Surgical and Oncological Characteristics of Early-Onset and Late-Onset Colorectal Cancers Over Five-Year Periods: A Single-Center 10-Year Experience**  
Arda Ulas Mutlu, Acibadem University, Istanbul, Türkiye
- 15:30 - 15:30      **116P - Improving Colorectal Cancer Detection with AI-Assisted Colonoscopy: A Systematic Review and Meta-Analysis of 38 RCTs With GRADE Assessment.**  
Israa Qutob, Alexandria University, Alexandria, Egypt
- 15:30 - 15:30      **117P - Predictors of significant lesions in colon capsule endoscopy**  
Lea Hansen, OUH - Odense University Hospital, Odense, Denmark



- 15:30 - 15:30      **118P - Evaluation of the Use of FOBT in Colorectal Cancer Screening in the Republic of Kazakhstan from 2011 to 2024**  
Abay Jumanov, Kazakh Research Institute of Oncology and Radiology-KazIOR, Almaty, Kazakhstan
- 15:30 - 15:30      **119P - Results of Colorectal Cancer Screening in the Republic of Kazakhstan over 14 Years (2011-2024)**  
Abay Jumanov, Kazakh Research Institute of Oncology and Radiology-KazIOR, Almaty, Kazakhstan
- 15:30 - 15:30      **120P - Linking Lynch Syndrome Gene Mutations to the Gut Microbiome profile: A Predictive Approach for Colorectal Cancer Risk**  
Elizabeth Half, Rambam Health Care Campus, Haifa, Israel
- 15:30 - 15:30      **121P - Deep learning can predict MSI/MMR status from primary and metastatic colorectal tissue slides**  
Salim Arslan, Panakeia Technologies Ltd., London, United Kingdom
- 15:30 - 15:30      **122P - Exosomal miR-382-5p inhibits pre-metastatic niche formation in colorectal cancer liver metastasis by targeting GPR176/GNAS-CXCR1/CXCR2 axis**  
Lingling Yang, The Second Affiliated Hospital of Nanchang University, Nanchang, China
- 15:30 - 15:30      **123P - Improved Adoptive T Cell Therapies for Colorectal Liver Metastases by Stabilization of IFNAR1 on Tumor-Specific T-Cells**  
Andrea Castiglioni, IRCCS Ospedale San Raffaele, Milan, Italy
- 15:30 - 15:30      **124P - Synthetic lethality of CBM signalosome inhibition for KRAS-Mutant Colorectal Cancers**  
Yi Yao, HotSpot Therapeutics, Boston, United States of America
- 15:30 - 15:30      **125P - Novel CBM signalosome inhibitor revealed the essentiality of CBM signalosome for KRAS mutant colorectal cancer**  
Fang Wang, HotSpot Therapeutics, Boston, United States of America
- 15:30 - 15:30      **126P - MetaCoLon project: The interaction between Nuclear Related factor-2 (Nrf2) signaling pathway and Pyruvate kinase isozyme M2 (PKM2) metabolic pathway in colon cancer**  
Stavroula Manolakou, Gastrointestinal Cancer Study Group, Heraklion, Greece
- 15:30 - 15:30      **127P - GPX2 enhance MSI-H colorectal cancer sensitivity towards 5-FU**  
Mahjabina Turi, Department of Oncology Shapingba Hospital affiliated to Chongqing University, Chongqing University, Chongqing, China
- 15:30 - 15:30      **128P - Cytotoxicity of arfolitixorin versus leucovorin (LEU) with 5-fluorouracil (5FU) and oxaliplatin in colorectal cancer (CRC) patient-derived tumoroids (PDTs)**  
Peter Eide, Ullernchausséen 64, Oslo, Norway



- 15:30 - 15:30      **129eP - A stop-and-go randomized study of FOLFOX4 or FOLFOX7 in advanced colorectal cancer using oxaliplatin**  
Sharmin Talukder, Combined military hospital, Dhaka, Bangladesh
- 15:30 - 15:30      **130eP - From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer**  
Yue Gou, Central South University, Changsha, China
- 15:30 - 15:30      **131eP - Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment**  
Lu Han, The Chinese PLA General Hospital, Beijing, China
- 15:30 - 15:30      **132eP - Prognostic uncertainty in refractory mCRC: evaluating outcomes with TAS-102 plus bevacizumab beyond traditional classification in a real-world setting**  
Pedro Frazão, Unidade Local de Saúde de Lisboa Ocidental, E.P.E., Lisboa, Portugal
- 15:30 - 15:30      **133eP - A Multicentric Real-World Study Comparing TAS-102 Alone vs. TAS-102 with Bevacizumab in mCRC Treatment**  
Telma Martins, Hospital Prof. Dr Fernando Fonseca EPE (Hospital Amadora/Sintra), Amadora, Portugal
- 15:30 - 15:30      **134eP - Observed Survival Following Treatment With Leronlimab In Patients With Metastatic Colorectal Cancer.**  
Ari Baron, Pacific Hematology Oncology Associates, San Francisco, United States of America
- 15:30 - 15:30      **135eP - Nutrition and chemotherapy tolerance in moroccan patients with metastatic colorectal cancer**  
Safaa Kriouile, National Institute of Oncology, Rabat, Morocco
- 15:30 - 15:30      **136eP - Nutritional intervention access in colorectal cancer patients: Findings from a National Administrative registry in Colombia**  
Sandra Puentes Sanchez, Cuenta de Alto Costo, Bogota, Colombia
- 15:30 - 15:30      **137eP - Diagnostics of the level of immunoglobulins (Ig), tumor markers (TM) and proteins in the plasma and supernatant before and after treatment in patients with colorectal cancer (CRC) taking into account modern approaches to proteomics.**  
Innara Turkpenova, Kazakh Research Institute of Oncology and Radiology-KazIOR, Almaty, Kazakhstan
- 15:30 - 15:30      **138eP - Circulating Tumor DNA Correlation to Disease Recurrence in Early and Advanced Colorectal Cancers**  
Shipra Maheshwari, University of Virginia Health System, Charlottesville, United States of America



- 15:30 - 15:30      **139eP - Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)**  
Zhenghang Wang, Peking University Cancer Hospital and Institute, Beijing, China
- 15:30 - 15:30      **140eP - Value of baseline modified Glasgow prognostic score and sarcopenia as predictive tools in colorectal cancer prognosis**  
Wafa Khemiri, University of Tunis El Manar - Faculty of Medicine; FSI Hospital, La Marsa, Tunisia
- 15:30 - 15:30      **141eP - Prognostic Value of Circulating Tumor DNA (ctDNA) in Colorectal Cancer: A Systematic Review and Meta-analysis**  
Sugat Adhikari, Shreegaun Primary Health Care Center, Dang, Nepal
- 15:30 - 15:30      **142eP - The Oncological Safety of Single-Incision Laparoscopic Surgery versus Conventional Laparoscopic Surgery in Colorectal Cancer - A Pilot Study**  
Liz Baker, North Tees and Hartlepool NHS Foundation Trust, Stockton on Tees, United Kingdom
- 15:30 - 15:30      **143eP - Rethinking Adjuvant Chemotherapy in Colon Cancer Patients Aged ≥65: Survival and Prognostic Factors**  
Zeliha Birsin, Istanbul University-Cerrahpasa - Faculty of Medicine, Istanbul, Türkiye
- 15:30 - 15:30      **144eP - Newly isolated lactic acid bacteria with potential probiotic properties, alleviates colorectal cancer in murine model**  
Elnaz Ghorbani, Mashhad University of Medical Sciences, Mashhad, Iran
- 15:30 - 15:30      **145TiP - FOG-001 – a first-in-class direct  $\beta$ -catenin:TCF inhibitor, in patients (pts) with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors: phase 1/2 study design**  
Kyriakos Papadopoulos, START - South Texas Accelerated Research Therapeutics, San Antonio, United States of America
- 15:30 - 15:30      **146TiP - MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progress**  
Xinxiang Li, Fudan University Shanghai Cancer Center, Shanghai, China
- 15:30 - 15:30      **147eTiP - Diet and Physical Activity Program in Colorectal Cancer Survivor (DPAP): A research protocol for phase II randomized controlled trial**  
Wala Ben Kridis, University of Sfax - Hopital Habib Bourguiba, Sfax, Tunisia
- 15:30 - 15:30      **151P - Matching-adjusted indirect comparisons (MAICs) of nivolumab + ipilimumab (N + I) vs durvalumab + tremelimumab (D + T) and atezolizumab + bevacizumab (A + B) for first-line (1L) unresectable hepatocellular carcinoma (uHCC)**  
Masatoshi Kudo, Kindai University Hospital, Osaka-Sayama, Japan

- 15:30 - 15:30      **152P - MORPHEUS-Liver: A Phase Ib/II, randomised study evaluating tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients (pts) with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)**  
Richard Finn, UCLA - David Geffen School of Medicine, Los Angeles, United States of America
- 15:30 - 15:30      **153P - Evolution of second-line practices in the era of immunotherapy: real-life data from the French prospective CHIEF cohort**  
Marie Decraecker, CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, France
- 15:30 - 15:30      **154P - Real-world systemic treatment patterns and outcomes in patients with hepatocellular carcinoma (HCC): experience from the UK South East Midlands Oncology Centre, 2019-2024**  
Ali Abdulnabi Suwaidan, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
- 15:30 - 15:30      **155P - Real-world data of HCC patients treated in 10 Brazilian centers 2017-2022.**  
Diogo Bugano Diniz Gomes, Albert Einstein Israelite Hospital, Sao Paulo, Brazil
- 15:30 - 15:30      **156P - Outcomes of durvalumab (D) with or without tremelimumab (T) in routine clinical practice according to HIMALAYA Trial Eligibility: results of the international DT-Real study**  
Ciro Celsa, Imperial College London - Hammersmith Campus, London, United Kingdom
- 15:30 - 15:30      **157P - Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analyses**  
Shukui Qin, Nanjing Tianyinshan Hospital of China Pharmaceutical University, Nanjing, China
- 15:30 - 15:30      **158P - Atezolizumab plus bevacizumab as first-line therapy in unresectable HCC: final analysis from phase IIIb AMETHISTA study**  
Lorenza Rimassa, Humanitas University, Pieve Emanuele (Milan), Italy
- 15:30 - 15:30      **159P - ATHECA: Final safety and efficacy analysis of a phase IIIb study of atezolizumab + bevacizumab in Spanish patients with unresectable HCC**  
Maria Elisa Reig Monzon, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
- 15:30 - 15:30      **160P - Comparative Effectiveness of Atezolizumab plus Bevacizumab versus Tremelimumab plus Durvalumab in a Real-World Setting**  
Federica Lo Prinzi, Policlinico Universitario Campus Bio-Medico, Rome, Italy
- 15:30 - 15:30      **161P - Real-world outcomes for unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab plus bevacizumab (A+B) in the United States (US)**  
David Pinato, Hammersmith Hospital, London, United Kingdom
- 15:30 - 15:30      **162P - Crossing the 3-Year Mark: Real-World Outcomes of Atezolizumab-Bevacizumab for Advanced HCC**  
Francesco Tovoli, University of Bologna - Dipartimento di Scienze Mediche e Chirurgiche, Bologna, Italy



- 15:30 - 15:30      **163P - Are clinical factors useful for identifying primary progressors (PP) in patients (pts) with hepatocellular carcinoma (HCC) undergoing first-line treatment with atezolizumab plus bevacizumab (AB)? Analysis from the Italian ARTE database**  
Silvia Cesario, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Pisa, Italy
- 15:30 - 15:30      **164P - Increase in LAG3-Positive CD8+ T cells after atezolizumab plus bevacizumab therapy as a predictor of progression-free survival in unresectable hepatocellular carcinoma**  
Tomoharu Yamada, The University of Tokyo Hospital, Bunkyo-ku, Japan
- 15:30 - 15:30      **165P - Early Bevacizumab Discontinuation (EBD) Does Not Impact Outcomes in Patients with Advanced Hepatocellular Carcinoma (HCC) Treated with Atezolizumab-Bevacizumab (AB)**  
Daniela Carvalho, A.C.Camargo Cancer Center - Centro Internacional de Pesquisa (CIPE), Sao Paulo, Brazil
- 15:30 - 15:30      **166P - Prognostic value of patients with unresectable hepatocellular carcinoma who achieved a radiographic complete response following immunotherapy-based conversion therapy**  
Da-Long Yang, Guangxi Medical University Affiliated Tumour Hospital, Nanning, China
- 15:30 - 15:30      **167P - UCHL1 Hijacks Tolerogenic Dendritic Cell Maturation and Promotes mregDC-Treg Crosstalk to Nullify Checkpoint Blockade**  
Yufei Zhao, Zhongshan Hospital Fudan University, Shanghai, China
- 15:30 - 15:30      **168P - Real world experience of immune checkpoint inhibitors in Hepatocellular carcinoma from India-Efficacy and liver related toxicity**  
Namratha Udupa M S, Nanjappa Lifecare Hospital, Shimoga, Karnataka, India
- 15:30 - 15:30      **169P - Efficacy and Safety of Quadruple-Modality Therapy (TACE, Radiotherapy, Targeted Therapy, and Immunotherapy) in Intermediate and Advanced Unresectable Hepatocellular Carcinoma: A Prospective Phase II Study**  
Nuoya Li, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
- 15:30 - 15:30      **170P - Efficacy and Safety of Atezolizumab plus Bevacizumab Combined with Transcatheter Arterial Embolization and Hepatic Arterial Infusion Chemotherapy in Large Unresectable Hepatocellular Carcinoma**  
Jinpeng Li, Shandong Cancer Hospital and Institute, Jinan, China
- 15:30 - 15:30      **171P - Transarterial chemoembolization (TACE) with or without anti-PD1/PD-L1 systemic therapy in unresectable hepatocellular carcinoma: a meta-analysis of randomized clinical trials**  
Henrique Kim, A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, Brazil

- 15:30 - 15:30      **172P - Final Analysis of A Randomized, Double Blind, Phase 2 Study of Sorafenib With or Without YIV-906 in Patients With Advanced HCC**  
Ghassan Abou-Alfa, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America
- 15:30 - 15:30      **173P - Dose escalation STRATeGy of regorafenib in Advanced HepatoCellular Carcinoma: phase II STRATA-HCC trial**  
Leonardo Fonseca, ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil
- 15:30 - 15:30      **174P - A Phase II, non-randomized, single arm, translational study of Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to first line Treatment (the IKF-t018 AURORA trial)**  
Arndt Vogel, Medizinische Hochschule Hannover and University of Toronto, Toronto General Hospital, Princess Margaret Cancer Centre, Hannover / Toronto, Germany
- 15:30 - 15:30      **175P - Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study.**  
Pasquale Lombardi, Imperial College London, London, United Kingdom
- 15:30 - 15:30      **176P - Tegavivint, a downstream Wnt/ $\beta$ -catenin inhibitor: interim results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC)**  
Daneng Li, City of Hope Comprehensive Cancer Center, Duarte, United States of America
- 15:30 - 15:30      **177P - Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310)**  
Richard Kim, Moffitt Cancer Center, Tampa, United States of America
- 15:30 - 15:30      **178P - Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma**  
Pasquale Lombardi, Imperial College London, London, United Kingdom
- 15:30 - 15:30      **179P - Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis**  
Francesca Salani, University of Pisa, Pisa, Italy
- 15:30 - 15:30      **180P - TAE-HAIC combined with lenvatinib plus camrelizumab or sintilimab plus bevacizumab for unresectable HCC with high tumor burden: a retrospective comparison**  
Jinpeng Li, Shandong Cancer Hospital and Institute, jinan, China
- 15:30 - 15:30      **181P - Hepatic arterial infusion chemotherapy in patients with unresectable hepatocellular carcinoma: 3-year survival update**  
Shiguang Chen, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China





- 15:30 - 15:30      **182P - Real-World Outcomes of Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma: A 10-Year Retrospective Study from a Swiss Tertiary Cancer Center**  
Guido Pesola, Oncology Institute of Southern Switzerland (IOSI)- Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
- 15:30 - 15:30      **183P - Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population**  
Jiaping Li, 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 15:30 - 15:30      **184P - Feraheme-enhanced MRI-guided Liver SBRT on 1.5T MR-Linac in Patients with Hepatocellular Carcinoma and Advanced Cirrhosis**  
Parisa Shamsesfandabadi, Allegheny Health Network Cancer Institute, Pittsburgh, United States of America
- 15:30 - 15:30      **185P - Transarterial Radioembolization in hepatocellular carcinoma patients with curative intent: A pooled, retrospective analysis of two studies in Europe**  
Dirk Arnold, Asklepios Klinik Altona - Hämatologie, internistische Onkologie, Palliativmedizin und Rheumatologie, Hamburg, Germany
- 15:30 - 15:30      **186P - Safety and response to neoadjuvant lenvatinib for poor-prognosis BCLC A hepatocellular carcinoma treated by percutaneous ablation in a curative intent: preliminary analysis of the French LENVABLA multicentre phase 2 trial (NCT05113186).**  
Pierre Nahon, APHP, Paris, France
- 15:30 - 15:30      **187P - Neoadjuvant immunotherapy is associated with a recurrence free survival benefit versus active surveillance in patients with resected hepatocellular cancer**  
Leonardo Brunetti, Imperial College London - Hammersmith Hospital, London, United Kingdom
- 15:30 - 15:30      **188P - Histomorphologic Features Characterising Response to Neoadjuvant Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma**  
Aria Torkpour, Imperial College London - Hammersmith Campus, London, United Kingdom
- 15:30 - 15:30      **189P - Reappraisal of alpha-fetoprotein (AFP) for early relapse detection after hepatocellular carcinoma (HCC) resection or transplantation**  
Giorgio Patelli, Università degli Studi di Milano Statale, Milan, Italy
- 15:30 - 15:30      **190P - Prognostic Scoring System for Hepatocellular Carcinoma: Risk Stratification and Survival Prediction in a Thai Cohort**  
Sunee Neesanun, Sawan Pracharak Hospital in affiliation with faculty of Medicine, Praboromrajchanok Institute., Nakhon Sawan, Thailand
- 15:30 - 15:30      **191P - Leveraging DNA Remnants in Red Blood Cells for Early Detection of Liver Cancer**  
Xingyun Yao, Westlake University, Hangzhou, China



- 15:30 - 15:30      **192P - The prognostic value of choline PET/CT in the initial assessment of patients with hepatocellular carcinoma**  
Hugo Couvert, Institute Jules Bordet, Brussels, Belgium
- 15:30 - 15:30      **193P - Multidisciplinary Teams (MDTs) for Hepatocellular Carcinoma (HCC): Maturity and optimal practices in Europe and Canada (EUCAN)**  
Arndt Vogel, University of Toronto - Institute of Medical Science, Toronto, Canada
- 15:30 - 15:30      **194P - Combined hepatocellular cholangiocarcinoma: A population-based retrospective study**  
Takashi Kokudo, NCGM - Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, Japan
- 15:30 - 15:30      **195P - Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinoma**  
Xianxiang Chen, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- 15:30 - 15:30      **196P - The role and mechanism of peroxisomes in the response to TACE treatment for hepatocellular carcinoma**  
Wen Jie, 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 15:30 - 15:30      **197P - In vivo bioluminescence imaging to study NF-κB-related tumor progression in primary liver cancer**  
Marie Schmid, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany
- 15:30 - 15:30      **198P - The Impact of HLA-E and IFNL4 Genes on Hepatocellular Carcinoma (HCC) Development and Progression in Hepatitis C Virus (HCV)-infected Patients (VERYMARKERS Study)**  
Luisa Foltran, CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, Italy
- 15:30 - 15:30      **199P - Research on the Therapeutic Mechanism of ACC-Bi2S3 Photothermal Composite Nanomaterials in TACE**  
Wanqing Shen, 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 15:30 - 15:30      **200P - Targeting hypoxia-inducible factor 1α to suppress hypoxia-mediated progression and invasion of hepatocellular carcinoma**  
Tania Payo-Serafín, Universidad de León, León, Spain
- 15:30 - 15:30      **201P - Exploring differentially expressed genes associated with HIF1A and tumor proliferation in hepatocellular carcinoma: bioinformatics and in vivo study**  
Jennifer Martínez-Geijo, Institute of Biomedicine (IBIOMED) - Universidad de León, Leon, Spain
- 15:30 - 15:30      **202P - Investigating Molecular Pathways of Acquired Resistance to Lenvatinib in Hepatocellular Carcinoma: from Cellular Models to Patient-Derived Samples.**  
Luisa Amato, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy



- 15:30 - 15:30      **203eP - Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis**  
Minh Le, TMU - Taipei Medical University, Taipei City, Taiwan
- 15:30 - 15:30      **204eP - Validation of the ALICE Model for Predicting Postoperative Ascites After Liver Resection in Hepatocellular Carcinoma: A Comparison With ALBI and Child-Pugh Classification**  
Mai Nakamura, NCGM - Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, Japan
- 15:30 - 15:30      **205eP - Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib**  
Merin Babu, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi/Cochin, India
- 15:30 - 15:30      **206eP - Real World Efficacy and Safety of Anlotinib in Hepatocellular Carcinoma Previously Treated with Immune Checkpoint Inhibitors**  
Changzhen Shang, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
- 15:30 - 15:30      **207eP - LncRNA sONE: A Novel Therapeutic Hub in Hepatocellular Carcinoma Restoring NO Homeostasis and NK Cell Activation via miR-34a/ULBP2 Regulation**  
Sama Hozayen, GIU - German International University, Cairo, Egypt
- 15:30 - 15:30      **208eP - Hsa\_circ\_0000284 (circHIPK3) and Hsa\_circ\_0001944 (circBCBM) are Novel Biomarkers for Early Detection of HCV-Induced Hepatocellular Carcinoma**  
Rana Youness, GIU - German International University, Cairo, Egypt
- 15:30 - 15:30      **209eP - RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT Mechanism**  
Zheng Hua, Shapingba Hospital affiliated to Chongqing University Shapingba District People's Hospital of Chongqing Chongqing 400030, P.R. China., Chongqing, China
- 15:30 - 15:30      **224P - Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)**  
Feng Tian, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- 15:30 - 15:30      **225P - Updated results and first biomarker analysis of a phase II trial combining nivolumab (nivo) and total neoadjuvant treatment (TNT) for locally advanced rectal cancer (LARC) (CA209-8M4)**  
Baruch Brenner, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
- 15:30 - 15:30      **226P - Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results**  
Changqing Jing, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

- 15:30 - 15:30      **227P - Surgical outcomes post-total mesorectal excision in patients with locally advanced rectal cancer undergoing total neoadjuvant treatment with short-course radiotherapy followed by chemo-immunotherapy: Data from the phase II Averectal trial.**  
Ali Shamseddine, AUBMC - American University of Beirut Medical Center, Beirut, Lebanon
- 15:30 - 15:30      **228P - Neoadjuvant Chemoradiotherapy Combined with Tislelizumab for Locally Advanced Rectal Cancer: A Phase II Clinical Trial**  
Yan Xu, Qingdao Central Hospital, Qingdao, China
- 15:30 - 15:30      **229P - Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer – clinical and quality of life analysis (NCT03997435)**  
Connie Ka Yan Lai, The Chinese University of Hong Kong, Sha Tin, Hong Kong SAR, China
- 15:30 - 15:30      **230P - Long-term follow-up of a nationwide cohort of patients with locally advanced rectal cancer treated with total neoadjuvant treatment according to the LARCT-US schedule and risk factors for recurrence**  
Israa Imam, Akademiska Sjukhuset Uppsala (Uppsala University Hospital), Uppsala, Sweden
- 15:30 - 15:30      **231P - Oncological Outcomes in Rectal Adenocarcinoma Patients Failing to Respond to Total Neoadjuvant Therapy**  
Emmanuel Mitry, IPC - Institut Paoli-Calmettes, Marseille, France
- 15:30 - 15:30      **232P - Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer (LARC): is practice matching the evidence? Real-world experience from Uruguay**  
Santiago Fontes, Asociacion Española Primera En Salud, Montevideo, Uruguay
- 15:30 - 15:30      **233P - Total Neoadjuvant Therapy(TNT) with RAPIDO in Rectal Adenocarcinomas: Real World Experience**  
Salman Shah, TMC - Tata Medical Center, Kolkata, India
- 15:30 - 15:30      **234P - Cardiotoxicity of Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer**  
Marianna Valzano, AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
- 15:30 - 15:30      **235P - Outcomes of a rectal cancer population treated with capecitabine-based chemoradiation compared with a cohort switched to S-1 for cardiotoxicity**  
Pia Osterlund, Tampere University Hospital (Tays), Tampere, Finland
- 15:30 - 15:30      **236P - Role of Rectal Cancer Neoadjuvant (Chemo)Radiotherapy in LARS Severity: Impact on Pelvic Floor Muscles**  
Sophio Khundadze, TSMU - Tbilisi State Medical University, Tbilisi, Georgia
- 15:30 - 15:30      **238P - Short-course radiotherapy for older patients with locally advanced rectal cancer and unfit for chemotherapy: The SOFT study**  
Gerardo Rosati, Azienda Ospedaliera Regionale San Carlo di Potenza, Potenza, Italy



- 15:30 - 15:30      **239P - Institutional prospective database of short course radiotherapy (SCRT) by Intensity modulated radiotherapy (IMRT) in rectal cancer - toxicity and quality of life (QOL) outcomes.**  
Trinanjana Basu, HCG Cancer Center, Maharashtra, India
- 15:30 - 15:30      **240P - Volumetric Modulated Arc Therapy for Women with Rectal Cancer: Is Vagina Sparing Achievable?**  
Mouna Ben Rejeb, Hôpital Abderrahmen Mami de Pneumo-Phisiologie, Ariana, Tunisia
- 15:30 - 15:30      **241P - Rationale for selecting the definitive stage of ultra-low anterior resection of the rectum**  
Mykola Gordiichuk, Shupyk National Healthcare University of Ukraine, Ministry of Health of Ukraine, Kyiv, Ukraine
- 15:30 - 15:30      **242P - Watch-and-Wait vs Direct Surgery in Low Rectal Cancer: A Comparative Outcome Analysis**  
Margarida Pereira, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa), Lisbon, Portugal
- 15:30 - 15:30      **243P - Clinical performance of Signatera Genome assay in a sub-cohort of locally advanced rectal cancer (LARC) patients (pts) in the MD Anderson INTERCEPT program**  
N. Arvind Dasari, MD Anderson Cancer Center, Houston, United States of America
- 15:30 - 15:30      **244P - Digital spatial profiling: Mapping tumor responses to radiotherapy in rectal cancer**  
Rachel Purcell, University of Otago, Christchurch, New Zealand
- 15:30 - 15:30      **245P - Correlation of Pathological Complete Response (pCR) to Survival Outcomes in Locally Advanced Rectal Cancer and Predictors to it: A Retrospective Study**  
Khaled Khalil, King Saud University, Riyadh, Saudi Arabia
- 15:30 - 15:30      **246P - Machine Learning-Based Prediction of Recurrence After Curative Treatment for Rectal Cancer: A Multi-Model Analysis from a Tertiary Cancer Centre**  
Umasankar Tantravahi, Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam, India
- 15:30 - 15:30      **247P - Prognostic Impact of Microsatellite Instability and Survival Disparities in Rectal Cancer: A SEER-Based Retrospective Analysis**  
Janani Arunachalam, UConn Health - University of Connecticut, Farmington, United States of America
- 15:30 - 15:30      **248P - Young onset rectal cancer (YORC): a descriptive tertiary center analysis**  
Cédric Schraepen, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium



- 15:30 - 15:30      **249P - Clinical Presentation and Histopathological Characteristics of Rectal Cancer in a Low and Middle Income Country.**  
Eben Aje, LUTH - Lagos University Teaching Hospital, Lagos, Nigeria
- 15:30 - 15:30      **250P - Rectal Cancer Care in LMIC : Insights, Challenges, and Outcomes**  
Haripriya Abbaraju, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, India
- 15:30 - 15:30      **251P - Clinical outcomes of rectal squamous cell carcinoma in British Columbia, Canada**  
Lei Yuan, UBC - University of British Columbia - Faculty of Medicine, Vancouver, Canada
- 15:30 - 15:30      **252P - Local and Symptomatic Control Evaluation in Palliative Radiotherapy for Rectal Adenocarcinoma in Frail, Elderly, or Metastatic Patients**  
Eva Bisson, Hopital Tenon AP-HP, Paris, France
- 15:30 - 15:30      **253P - Defining Fibroblast niches in Rectal Cancer**  
Helen Tyrrell, Kennedy Institute of Rheumatology, Oxford, United Kingdom
- 15:30 - 15:30      **254eP - Immunotherapy in dMMR/MSI Locally Advanced Rectal Cancer: A Real-World Retrospective Study from an Argentine Center.**  
Julian Maquieira, Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina
- 15:30 - 15:30      **255eP - Overall response to Total Neoadjuvant Therapy (TNT) followed by surgery in Locally Advanced Rectal Cancer: A Three and a Half Year Experience at a Tertiary Level Hospital in Bangladesh**  
Nowshin Taslima Hossain, AMCGH - Ahsania Mission Cancer and General Hospital, Dhaka, Bangladesh
- 15:30 - 15:30      **256eP - Comparative Outcomes of TNT and CRT in Locally Advanced Rectal Cancer: A Retrospective Cohort Study.**  
Sofia Ruffini Egea, Hospital Universitario Miguel Servet, Zaragoza, Spain
- 15:30 - 15:30      **257eP - Quality of life and long-term treatment outcomes following pelvic exenteration for locally advanced rectal cancer**  
Saidrahkim Lukmonov, Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan

|                      |                                                 |                       |
|----------------------|-------------------------------------------------|-----------------------|
| <b>16:30 - 18:00</b> | <b>Type: Educational session</b>                | <b>Room Barcelona</b> |
|                      | <b>Title: Symptom management in GI oncology</b> |                       |

- 16:30 - 16:50      **Treatment of pain in pancreatic cancer**  
Denis Dupoirion, ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, France
- 16:50 - 17:10      **How to manage cachexia and malnutrition**  
Marie Fallon, Cancer Research UK Edinburgh Centre, Edinburgh, United Kingdom



- 17:10 - 17:30 **Holistic approach to chemotherapy-induced neuropathy**  
Karin Jordan, Ernst von Bergmann Klinikum Potsdam, Potsdam, Germany
- 17:30 - 17:50 **Digital solutions to improve remote monitoring of symptoms**  
Stein Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway
- 17:50 - 18:00 **Q&A**

|                      |                                                                  |                    |
|----------------------|------------------------------------------------------------------|--------------------|
| <b>16:30 - 18:00</b> | <b>Type: Abstract session<br/>Title: Proffered Paper session</b> | <b>Room Madrid</b> |
|----------------------|------------------------------------------------------------------|--------------------|

- 16:30 - 16:40 **One LBA to announced**
- 16:40 - 16:50 **20 - Clinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance**  
N. Arvind Dasari, MD Anderson Cancer Center, Houston, United States of America
- 16:50 - 17:00 **30 - Association of ctDNA Clearance with Disease-Free Survival, Safety, and Quality of Life from ctDNA-Directed Therapy: Findings from the ALTAIR Study**  
Masahito Kotaka, Sano Hospital-Gastrointestinal Cancer Centre, Kobe, Japan
- 17:00 - 17:10 **Invited discussant 1 LBA to be announced, 20 and 30**
- 17:10 - 17:20 **Q&A**
- 17:20 - 17:30 **40 - Liquid biopsy-guided selection for anti-EGFR re-treatment in RAS/BRAF wild-type (wt) chemorefractory metastatic colorectal cancer patients (mCRC pts): Results from the phase II randomized PARERE trial**  
Paolo Ciracì, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
- 17:30 - 17:40 **50 - A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies**  
Ofer Purim, Shaare Zedek Medical Center, Jerusalem, Israel
- 17:40 - 17:50 **Invited Discussant 40 and 50**
- 17:50 - 18:00 **Q&A**



|                      |                                                                                                                                                                                                                                                                                                                                                                                                                                              |                      |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| <b>16:30 - 18:00</b> | <b>Type: Special session</b><br><b>Title: ESO special session: Forecast for colorectal cancer in the next 12 months</b><br>Chair(s): Eric Van Cutsem, Belgium; Sara De Dosso, Switzerland                                                                                                                                                                                                                                                    | <b>Room Valencia</b> |
| 16:30 - 16:35        | <b>Welcome and introduction from the chairs and the past-President of ESMO</b><br><u>Andres Cervantes</u> , Hospital Clinico Universitario de Valencia, Valencia, Spain                                                                                                                                                                                                                                                                      |                      |
| 16:35 - 16:45        | <b>Next-Gen screening for colorectal cancer</b><br><u>Frank Sinicrope</u> , Mayo Clinic - Rochester, Rochester, United States of America                                                                                                                                                                                                                                                                                                     |                      |
| 16:45 - 16:55        | <b>The colorectal cancer surgeon's perspective</b><br><u>Julio Garcia-Aguilar</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America                                                                                                                                                                                                                                                                       |                      |
| 16:55 - 17:10        | <b>The medical oncologist's perspectives on: Localized rectal cancer, localized colon cancer, and advanced colon cancer</b><br><u>Eric Van Cutsem</u> <sup>1</sup> , <u>Sara De Dosso</u> <sup>2</sup> , <sup>1</sup> UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium, <sup>2</sup> EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland |                      |
| 17:10 - 17:20        | <b>The radiation oncologist's perspective</b><br><u>Veronique Vendrely</u> , CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, France                                                                                                                                                                                                                                                                                                            |                      |
| 17:20 - 17:35        | <b>The nurse's perspective</b><br><u>Tihana Gašpert</u> , University Hospital KBC Rijeka, Rijeka, Croatia                                                                                                                                                                                                                                                                                                                                    |                      |
| 17:35 - 17:45        | <b>The patient advocate's perspective</b><br><u>Zorana Maravic</u> , DiCE - Digestive Cancers Europe vzw/asbl, Overijse, Belgium                                                                                                                                                                                                                                                                                                             |                      |
| 17:45 - 18:00        | <b>Panel discussion of the hottest topics in colorectal cancer in 2024</b>                                                                                                                                                                                                                                                                                                                                                                   |                      |
| <b>18:15 - 19:15</b> | <b>Type: Industry Satellite Symposium</b><br><b>Title: GSK - What is the role of IO, biomarker testing and the MDT in locally advanced dMMR/MSI-H CRC?</b><br>Chair(s): Rocio Garcia-Carbonero, Spain; Christopher Williams, United Kingdom; Gertjan Rasschaert, Belgium                                                                                                                                                                     | <b>Room Bilbao</b>   |
| 18:15 - 18:20        | <b>What are the existing unmet needs of patients with dMMR/MSI-H LARC and LACC?</b><br><u>Christopher Williams</u> , UL - University of Leeds, Leeds, United Kingdom                                                                                                                                                                                                                                                                         |                      |
| 18:20 - 18:30        | <b>How is IO being investigated in dMMR/MSI-H LARC and LACC?</b><br><u>Gertjan Rasschaert</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium                                                                                                                                                                                                                                                               |                      |





- 18:30 - 18:50      **Discussion 1: What potential role may IO have in the clinical management of dMMR/MSI-H LARC and LACC?**  
Rocio Garcia-Carbonero<sup>1</sup>, Christopher Williams<sup>2</sup>, Gertjan Rasschaert<sup>3</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, Spain, <sup>2</sup>UL - University of Leeds, Leeds, United Kingdom, <sup>3</sup>UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
- 18:50 - 19:10      **Discussion 2: What is the role of biomarker testing and the MDT in treatment decisions for dMMR/MSI-H LARC and LACC?**  
Rocio Garcia-Carbonero<sup>1</sup>, Christopher Williams<sup>2</sup>, Gertjan Rasschaert<sup>3</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, Spain, <sup>2</sup>UL - University of Leeds, Leeds, United Kingdom, <sup>3</sup>UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
- 19:10 - 19:15      **General Q&A/panel discussion**  
Rocio Garcia-Carbonero<sup>1</sup>, Christopher Williams<sup>2</sup>, Gertjan Rasschaert<sup>3</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, Spain, <sup>2</sup>UL - University of Leeds, Leeds, United Kingdom, <sup>3</sup>UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium

**18:15 - 19:15      Type: Industry Satellite Symposium      Room Malaga**  
**Title: Incyte - Rare GI tumours: Transformations in the treatment landscape**  
Chair(s): Sheela Rao, United Kingdom

- 18:15 - 18:20      **Introduction and welcome**  
Sheela Rao, The Royal Marsden Hospital - Chelsea, London, United Kingdom

- 18:20 - 18:35      **Squamous anal cancer, current standard of care in a rare HPV-driven tumour**  
Filippo Pietrantonio, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

- 18:35 - 18:50      **Evolving treatment landscape for patients with locally advanced or metastatic SCAC and the recent advancements of immunotherapy in the first-line treatment arsenal**  
Sheela Rao, The Royal Marsden Hospital - Chelsea, London, United Kingdom

- 18:50 - 19:05      **Cholangiocarcinoma, a rare disease with an increasing incidence where precision medicine has transformed the treatment landscape**  
Arndt Vogel, University of Toronto - Institute of Medical Science, Toronto, Canada

- 19:05 - 19:15      **Q&A and close of session**  
Sheela Rao, The Royal Marsden Hospital - Chelsea, London, United Kingdom

**18:15 - 19:15      Type: Industry Satellite Symposium      Room Valencia**  
**Title: Takeda - Treatment choice and influencing factors in previously treated mCRC: A case-based interactive discussion**  
Chair(s): Elena Elez Fernandez, Spain

- 18:15 - 18:20      **Welcome and introduction**  
Elena Elez Fernandez, Vall d'Hebron University Hospital, Barcelona, Spain



- 18:20 - 18:35      **Clinical scenario 1: Maximizing the value of available options - Sequencing of treatments in later-line therapy**  
Sara Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padua, Italy
- 18:35 - 18:50      **Clinical scenario 2: Tailoring treatment in patients refractory or intolerant to standard chemotherapies**  
Sebastian Stintzing, Charité - Universitätsmedizin Berlin, Berlin, Germany
- 18:50 - 19:05      **Clinical scenario 3: Integrating biomarker-directed therapy into mCRC treatment**  
Elena Elez Fernandez, Vall d'Hebron University Hospital, Barcelona, Spain
- 19:05 - 19:15      **Closing remarks and Q&A**



05.07.2025

|                      |                                                                                                                |                       |
|----------------------|----------------------------------------------------------------------------------------------------------------|-----------------------|
| <b>08:30 - 10:00</b> | <b>Type: Educational session</b><br><b>Title: Metastatic colon cancer</b><br>Chair(s): Chiara Cremolini, Italy | <b>Room Barcelona</b> |
|----------------------|----------------------------------------------------------------------------------------------------------------|-----------------------|

08:30 - 08:50      **Surgery for cure: From resection to liver transplantation**  
René Adam, Hôpital Paul Brousse AP-HP, Villejuif, France

08:50 - 09:10      **Right or left colon cancer: Does it remain a surrogate marker of efficacy of targeted therapy?**  
Chiara Cremolini, University of Pisa, Pisa, Italy

09:10 - 09:30      **Personalised medicine and metastatic colon cancer: Present and future**  
Takayuki Yoshino, National Cancer Center Hospital East, Kashiwa, Japan

09:30 - 09:50      **The evolution of immunotherapy in MSI tumours**  
Michael Overman, The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America

09:50 - 10:00      **Q&A**

|                      |                                                                  |                    |
|----------------------|------------------------------------------------------------------|--------------------|
| <b>08:30 - 10:00</b> | <b>Type: Abstract session</b><br><b>Title: Mini Oral session</b> | <b>Room Madrid</b> |
|----------------------|------------------------------------------------------------------|--------------------|

08:30 - 08:35      **389MO - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis**  
Eric Van Cutsem, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium

08:35 - 08:40      **390MO - Definitive Chemoradiotherapy for Adenocarcinoma of the Esophagus: a Dutch Population-Based Cohort**  
Sanjiv Gangaram-Panday, Erasmus MC, Rotterdam, Netherlands

08:40 - 08:45      **391MO - Phase III randomized IRIGA trial of FOLFIRINOX versus mFOLFOX6 as first-line treatment for patients with HER2-negative gastric and gastroesophageal adenocarcinoma**  
Daria Gavrilova, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation

08:45 - 08:57      **Invited Discussant 389MO, 390MO and 391MO**

08:57 - 09:02      **222MO - Tumor immune microenvironment and survival outcome following preoperative chemoradiotherapy in locally advanced rectal cancer: results from the STAR-01 study cohort**  
Francesca Negri, University Hospital of Parma, Parma, Italy



- 09:02 - 09:07 **223MO - Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): the ShorTrip study**  
Beatrice Borelli, Azienda Ospedaliero Universitaria Pisana, PISA, Italy
- 09:07 - 09:12 **7MO - Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): final results of the randomised phase II PANIRINOX-UCGI28 study**  
Thibault Mazard, ICM - Institut du Cancer de Montpellier, Montpellier, France
- 09:12 - 09:24 **Invited Discussant 261MO, 262MO and 7MO**
- 09:24 - 09:29 **261MO - A Phase II Study of Olaparib in patients (pts) with Advanced Biliary Tract Cancer (aBTC) with aberrant homologous recombinant repair (HRR) mutations**  
Daniel Ahn, Mayo Clinic, Phoenix, United States of America
- 09:29 - 09:34 **262MO - Preliminary efficacy outcomes of ivosidenib in patients with IDH1 mutated cholangiocarcinoma (mIDH1 CCA): initial results from the phase 3b ProviDHe study**  
John Bridgewater, UCL Cancer Institute - Paul O'Gorman Building, London, United Kingdom
- 09:34 - 09:39 **392MO - Recurrent Patient-Reported Outcome (PRO)-Based Deterioration Predicts Overall Survival (OS) in Patients with Advanced Gastric Adenocarcinoma with PD-L1 Score of  $\geq 5\%$ : Results from the RATIONALE-305 Trial**  
Markus Moehler, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany
- 09:39 - 09:44 **393MO - Overall survival in germline CDH1 pathogenic variant (PV) carriers: A Multicenter Comparative Analysis Study**  
Mara Cruellas Lapena, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain
- 09:44 - 09:59 **Invited discussant 262MO, 392MO and 393MO**

|                      |                                                                                                                                                                                          |                       |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| <b>10:00 - 10:30</b> | <b>Type: Coffee break</b><br><b>Title: Coffee break</b>                                                                                                                                  | <b>Foyer</b>          |
| <b>10:30 - 12:30</b> | <b>Type: Keynote session</b><br><b>Title: ESMO GI 2025 Keynote and take-home messages</b><br>Chair(s): Michel Ducreux, France; Teresa Macarulla Mercade, Spain; Eric Van Cutsem, Belgium | <b>Room Barcelona</b> |

- 10:30 - 10:55 **Lessons learned from GI translational research and the path forward**  
Josep Tabernero, Vall d'Hebron University Hospital, Barcelona, Spain
- 10:55 - 12:30 **Full session programme to be announced**